

Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition

Gregory C. Howard^a, Jing Wang^{b,c}, Kristie Lindsey Rose^{d,e}, Purvi Patel^e, Tina Tsui^e, Andrea C. Florian^{a,f}, Shelly L. Lorey^a, Brian C. Grieb^{a,g}, Brianna N. Smith^g, Macey J. Slota^{a,h}, Elizabeth M. Reynolds^a, Soumita Goswami^a, Michael R. Savona^g, Taekyu Lee^d, Stephen W. Fesik^{d,h,i}, Qi Liu^{b,c}, and William P. Tansey^{a,d,*}

^aDepartment of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

^bDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA

^cCenter for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

^dDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

^eMass Spectrometry Research Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

^fCurrent address: Department of Biology, Belmont University, Nashville, TN 37212, USA

^hCurrent address: Department of Urology, University of California San Francisco, San Francisco CA 94143, USA

^gDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA

^hDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

ⁱDepartment of Chemistry, Vanderbilt University, Nashville, TN 37232, USA

*Corresponding author: Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232. Phone: 615-322-1993. Email: william.p.tansey@vanderbilt.edu

Summary

The chromatin-associated protein WDR5 is a promising target for cancer drug discovery, with most efforts blocking an arginine-binding cavity on the protein called the "WIN" site that tethers WDR5 to chromatin. WIN site inhibitors (WINi) are active against multiple cancer cell types in vitro, the most notable of which are those derived from MLL-rearranged (MLLr) leukemias. Peptidomimetic WINi were originally proposed to inhibit MLLr cells via dysregulation of genes connected to hematopoietic stem cell expansion. Our discovery and interrogation of small molecule WIN site inhibitors, however, revealed that they act in MLLr cell lines to suppress ribosome protein gene (RPG) transcription, induce nucleolar stress, and activate p53. Because there is no precedent for an anti-cancer strategy that specifically targets RPG expression, we took an integrated multi-omics approach to further interrogate the mechanism of action of WINi in MLLr cancer cells. We show that WINi induce depletion of the stock of ribosomes, accompanied by a broad translational choke, induction of a DNA damage response, and changes in alternative mRNA splicing that inactivate the p53 antagonist MDM4. We also show that WINi are synergistic with agents including venetoclax and BET-bromodomain inhibitors. Together, these studies reinforce the concept that WINi are a novel type of ribosome-directed anti-cancer therapy and provide a resource to support their clinical implementation in MLLr leukemias and other malignancies.

Introduction

WDR5 is a highly-conserved protein that moonlights in a variety of functions in the nucleus. It rose to prominence as a component of epigenetic writer complexes that deposit histone H3 lysine 4 (H3K4) methylation (Guarnaccia & Tansey, 2018), but was subsequently found to act outside these complexes to facilitate the integrity of the mitotic spindle (Ali et al, 2017), bookmark genes for reactivation after mitosis (Oh et al, 2020), and promote transcription of a subset of ribosomal protein genes [(RPGs); (Bryan et al, 2020)] via recruitment of the oncoprotein transcription factor MYC to chromatin (Thomas et al, 2019). WDR5 is also frequently overexpressed in cancer, where its overexpression correlates with aggressive disease and poor clinical outcomes (Guarnaccia & Tansey, 2018). Accordingly, WDR5 is an auspicious target for inhibition in a range of malignancies including MLL-rearranged (MLLr) leukemias (Aho et al, 2019a; Cao et al, 2014), MYC-driven cancers (Aho et al, 2019b), C/EBP α -mutant leukemias (Grebien et al, 2015), p53 gain-of-function cancers (Zhu et al, 2015), neuroblastomas (Bryan et al., 2020), rhabdoid tumors (Florian et al, 2022), and metastatic breast cancers (Cai et al, 2022).

Although WDR5 PROTACs have been described (Li et al, 2022; Yu et al, 2021), safety concerns over destroying a pan-essential protein such as WDR5 (Siladi et al, 2022) means that most drug discovery efforts have focused on small molecule inhibition of key binding sites on the protein. Some initiatives target a hydrophobic cleft on WDR5 known as the "WDR5-binding motif" (WBM) site (Chacon Simon et al, 2020; Macdonald et al, 2019) that contacts MYC (Thomas et al, 2015). But the majority of efforts target the "WDR5-interaction" (WIN) site of WDR5 (Guarnaccia & Tansey, 2018)—an arginine binding cavity that tethers WDR5 to chromatin (Aho et al., 2019a) and makes contact with partner proteins carrying an arginine-containing "WIN" motif (Guarnaccia et al, 2021). Multiple WIN site inhibitors (WINi) have been described (Aho et al., 2019a; Bolshan et al, 2013; Cao et al., 2014; Chen et al, 2021a; Chen et al, 2021b; Grebien et al., 2015; Karatas et al, 2017; Karatas et al, 2013; Li et al, 2016; Senisterra et al, 2013; Tian et al, 2020; Wang et al, 2018), including those that are orally bioavailable and have anti-tumor activity *in vivo* (Chen et al., 2021b; Teuscher et al, 2023). Given the intense interest in developing WINi for cancer therapy, and the rapid pace of improvement in these molecules, it is likely that WIN site inhibitors will be ready for clinical vetting in the near future.

That said, controversy remains regarding the mechanism of action of WIN site inhibitors, even in the context of MLLr leukemias, where there is strong empirical support for their utility. MLL-rearranged leukemias are defined by translocation of one copy of *MLL1*—a gene that encodes one of six MLL/SET proteins that are the catalytic subunits of the histone methyltransferase (HMT) complexes responsible for H3K4 methylation (Guarnaccia & Tansey, 2018). The near universal retention of a pristine copy of *MLL1* in these cancers led to the idea that MLLr leukemias depend on wild-type MLL1 to support the activity of oncogenic MLL1-fusion oncoproteins (Thiel et al, 2010)—a function in turn that depends on insertion of a low affinity WIN motif within MLL1 into the WIN site of WDR5 (Alicea-Velazquez et al, 2016). Consistent with this notion, early peptidomimetic WINi are active against MLLr leukemia cells *in vitro* and are reported to suppress levels of H3K4 methylation at canonical MLL1-fusion target genes such as the *HOXA* loci, causing cellular inhibition through a combination of differentiation and apoptosis (Cao et al., 2014). Subsequently, however, wild-type MLL1 was shown to be dispensable for transformation by MLL-fusion oncoproteins (Chen et al, 2017), and our analysis of picomolar small

molecule WINi revealed that they act in MLLr cells without inducing significant changes in the expression of *HOXA* genes or levels of H3K4 methylation (Aho et al., 2019a). Instead, WIN site inhibitors displace WDR5 from chromatin and directly suppress the transcription of ~50 genes, the vast majority of which are connected to protein synthesis, including half the cohort of RPGs. We also found that WINi provoke nucleolar stress and induce p53-dependent cell death. Based on our findings, we proposed that WIN site inhibitors kill MLLr cells via depletion of part of the ribosome inventory that induces apoptosis via a ribosome biogenesis stress response.

The concept of ribosome-directed cancer therapies is not new (Laham-Karam et al, 2020; Temaj et al, 2022). Besides mTOR and translational inhibitors, one of the most prevalent strategies in this realm is inhibition of ribosomal RNA (rRNA) production or processing, which is a feature of both existing chemotherapies such as platinum-containing compounds (Bruno et al, 2017), as well as newer targeted RNA polymerase I inhibitors (Drygin et al, 2011; Peltonen et al, 2014). Although these agents exert their anti-cancer effects through multiple mechanisms (Laham-Karam et al., 2020), they are generally thought to disrupt the stoichiometry of RNA and protein components of the ribosome, leading to an excess of ribosomal proteins that inactivate MDM2 to induce p53-dependent cancer cell death. The paradigm we developed for WINi is modeled after that of rRNA inhibitors, although it is important to note that a significant point of divergence from rRNA poisons is that in this model WINi induce p53 not by promoting ribosomal protein accumulation, but by causing a selective imbalance in the ribosome subunit inventory. How such an imbalance could lead to p53 induction, as well as other consequences it may have on MLLr cellular processes, remains unknown.

Fortifying understanding of the mechanism of action of WINi in MLLr cancer cells is key to their clinical implementation. At present, there is no precedent for the mechanism we propose, no understanding of the impact of selective ribosome subunit depletion on translation or other tumor-relevant processes, and no expectations for how resistance to WINi could emerge or how their anti-tumor actions could be made more effective. To ameliorate these deficiencies, we took an integrated multiomics approach, combining transcriptional and translational profiling with genome-wide CRISPR screens to probe WINi action in MLLr cells. Our studies show that although the transcriptional effects of WINi on ribosome subunit expression are confined to those RPGs directly regulated by WDR5, effects at the protein level are not, and WIN site inhibition leads to diminution of the entire stock of cytosolic ribosomes. Ribosome subunit attrition is accompanied by a broad translational choke, induction of a DNA damage response, and activation of p53—driven largely via RPL22-dependent alternative splicing of the p53 antagonist MDM4. We also show that WINi are synergistic with approved and targeted agents including venetoclax and BET-bromodomain inhibitors. Collectively, these findings solidify a novel mechanism of action for WIN site inhibitors in MLLr cells and highlight a path for their optimal clinical implementation.

Results

Impact of WINi on the transcriptome of MLLr cancer cells

Our model for the action of WINi in MLLr leukemia cells is based on analysis of two early generation compounds (Aho et al., 2019a): C3 ($K_d = 1.3$ nM) and C6 ($K_d = 100$ pM). Subsequently (Tian et al., 2020), we discovered more potent molecules such as C16 ($K_d < 20$ pM) that have not been extensively profiled. To ask if improvements in the potency of WINi have resulted in divergent activities, we first compared C6 with C16 (**Figure 1A**). Both molecules bind the WIN site of WDR5 (**Figure 1B** and **Figure 1—figure supplement 1A**), but differ in affinity due to a bicyclic dihydroisoquinolinone core that locks C16 into a favorable binding conformation (**Figure 1C**). Consistent with its higher affinity, C16 is ~20 times more potent than C6 in inhibiting MV4;11 (MLL–AF4) and MOLM13 (MLL–AF9) leukemia lines (**Figure 1—figure supplement 1B–C**): In MV4;11 cells, for example, the GI_{50} for C6 is 1 μ M, compared to 46 nM for C16. These differences in potency are reflected at the level of RPG suppression. Using a target engagement assay (Florian et al., 2022) that measures transcript levels from seven RPGs—five (*RPS14*, *RPS24*, *RPL26*, *RPL32*, and *RPL35*) that are always bound by WDR5 and two (*RPS11* and *RPS14*) that are never bound—we observe that maximal suppression of RPG transcripts occurs at ~2 μ M for C6 and ~100 nM for C16 in MV4;11 (**Figure 1D**) and MOLM13 (**Figure 1—figure supplement 1D**) cells. To functionally compare these two inhibitors of different potencies, we used these RPG-normalized doses in all our subsequent studies.

We performed RNA-sequencing (RNA-Seq) on MV4;11 cells treated for 48 hours with DMSO, C6, or C16 (**Figure 1—figure supplement 1E** and **Figure 1—source data 1**). Both compounds elicit thousands of gene expression changes (**Figure 1E**), a majority of which are less than two-fold in magnitude (**Figure 1—figure supplement 1F**). We had previously performed RNA-Seq on MV4;11 cells treated with 2 μ M C6 and observed just ~75 induced and ~460 reduced transcripts (Aho et al., 2019a). In this earlier work, however, increased variance among replicates made it difficult for as many small gene expression changes to reach statistical significance as in the current study (**Figure 1—figure supplement 1G**). Comparing the new RNA-Seq datasets, we observe similar effects of C6 and C16 on the MV4;11 cell transcriptome (**Figure 1F**), with more than 80% of the transcripts altered by C16 altered in the same direction by C6 (**Figure 1G**). In both cases, suppressed genes are enriched in those bound by WDR5 in MV4;11 cells (**Figure 1H**); although a majority of transcriptional changes occur at loci bereft of detectable WDR5 binding (**Figure 1F**). For both compounds, expression of genes connected to protein synthesis, the cell cycle, DNA replication, mTORC signaling, and MYC are reduced, while expression of those connected to chemokine signaling, apoptosis and p53 are induced (**Figure 1I** and **Figure 1—source data 2**). Indeed, ~90 "consensus" p53 target genes (Fischer, 2017) are induced by C6/C16 (**Figure 1—figure supplement 2A–B**), including the tumor suppressor *ZMAT3* [**Figure 1F**; (Biegging-Rolett et al, 2020)]. Finally, we note that for both compounds, the transcriptional effects on RPG expression are almost entirely confined to those RPGs bound by WDR5 (**Figure 1J**). The conspicuous exception to this trend is *RPL22L1*—a paralog of *RPL22*—mRNA levels which are strongly reduced by C6/C16 (**Figure 1F** and **Figure 1J**). This feature of the response is not confined to MLLr cells, as *RPL22L1* expression is also decreased by WINi in sensitive rhabdoid tumor cell lines (Florian et al., 2022), but not in the insensitive K562 leukemia line (Bryan et al., 2020) (**Figure 1—**

figure supplement 2C). Despite not being a direct WDR5 target gene, therefore, *RPL22L1* expression is recurrently suppressed by WINi in responsive cancer cell lines.

Together, these data reveal that improvements in the potency of WINi have not resulted in substantive changes in their impact on the transcriptome of MLLr cells, and reinforce the concept that inhibition of select RPG expression—and induction of a p53-related transcriptional program—defines the response of the transcriptome to WIN site blockade in this setting.

Impact of WINi on the translome of MLLr cancer cells

Treatment of MV4;11 cells with 2 μ M C6 results in decreased translation, as measured by bulk labeling of nascent polypeptide chains with *O*-propargyl-puromycin (OPP) (Aho et al., 2019a). To determine more precisely the effects of WIN site inhibition on translational processes, we performed ribosome profiling [Ribo-Seq; (McGlinchy & Ingolia, 2017)] in parallel with the RNA-Seq analyses described above. By sequencing ribosome protected fragments (RPF) in treated and control cells, and normalizing to transcript levels from RNA-Seq, we calculated the translation efficiency (TE) of each transcript and used this to determine how C6/C16 influence translation, independent of effects on mRNA abundance.

In these experiments, RPF have the characteristic length of ribosome-protected mRNA fragments (28–32 nucleotides; **Figure 2—figure supplement 1A**), are enriched in coding sequences (**Figure 2—figure supplement 1B**), and map to the expected reading frame **Figure 2—figure supplement 1C**), all of which indicate successful profiling. In contrast to RNA-Seq, where we see equal numbers of transcript increases and decreases in response to C6/C16, the overwhelming translational effect of these compounds is inhibitory (**Figure 2A**). Of the ~10,000 transcripts profiled, between ~4,500 (C16) and ~5,900 (C6) transcripts show decreased TE, compared to less than 10 transcripts with increased translation (**Figure 2B** and **Figure 2—source data 1**). As we observed in the RNA-Seq, changes in TE are generally less than two-fold (**Figure 2A**) and there is extensive overlap between the two inhibitors, with ~90% of the transcripts decreased in TE by C16 also decreased by C6 (**Figure 2C**). In general, C6/C16 reduce translation of mRNAs in a manner independent of basal translation efficiencies (**Figure 2D**), although if we bin transcripts according to basal TE we observe that the number of highly-translated transcripts (fourth quartile) impacted by C6/C16 is greater than for those transcripts with lower basal TE (**Figure 2E**). Within these quartiles, however, the magnitude of reduction in TE is equivalent (**Figure 2—figure supplement 1D**). Interestingly, mRNAs carrying better matches to the 5'TOP motif—which links translation to mTORC1 signaling (Philippe et al, 2020)—show less decrease in TE compared to those with poorer matches (**Figure 2—figure supplement 1E**), suggesting that mTORC1-regulated mRNAs may be spared from the full translational effects of WIN site inhibition.

Interrogating specific changes in TE induced by C6/C16, we see that the biological categories of transcripts with decreased TE echo many of those observed with decreased mRNA levels, but include more genes in each category. For example, manually curating each list for transcripts encoding the ~60 validated substrates of the protein arginine methyltransferase PRMT5 (Radzisheuskaya et al, 2019) reveals that 42 are translationally suppressed by C6/C16, compared to just 10 that are suppressed at the mRNA level (**Figure 2—figure supplement 1F**). Probing for Hallmark categories in the Human

Molecular Signatures Database [MSigDB; (Liberzon et al, 2015)] uncovers the extent of this phenomenon (**Figure 2—source data 2**), with categories linked to MYC, E2F, mTORC1 signaling, and the G2M checkpoint (**Figure 2F**) all represented by more genes in the ribosome profiling than in the RNA-Seq experiments. Within these categories, a majority of genes suppressed by C6/C16 at the mRNA level are also further suppressed translationally (**Figure 2—figure supplement 1G**). This is not a general trend in the response, however, as fewer than half of the total transcripts with reduced mRNA abundance experience this additional translational inhibition (**Figure 2—figure supplement 1H**). The finding that TE changes induced by C6/C16 extend the biological characteristics of changes in mRNA abundance may indicate a role for impaired translation in contributing to at least some of the mRNA level differences triggered by WINi. Indeed, comparing transcripts with decreased TE but no mRNA decrease with transcripts with decreased TE and mRNA levels reveals the latter are enriched in so-called "optimal codons" (Wu et al, 2019) that normally promote mRNA stability but are linked to mRNA instability when translation is inhibited (**Figure 2—figure supplement 1I**).

Implicit in the previous discussion, a majority of the translational decreases triggered by C6/C16 occur at transcripts for which there are no significant changes in mRNA abundance (**Figure 2—figure supplement 1H**). Expectedly, genes with decreased TE but no mRNA level changes are enriched in several of the major Hallmark categories described above (**Figure 2—source data 3**). But we also observe enrichment in genes connected to the proteasome, spliceosome, mRNA surveillance, and translation (**Figure 2G**). The latter category includes subunits of the mitochondrial ribosome (**Figure 2—figure supplement 2A**), translation and ribosome biogenesis factors, and an expanded cohort of transcripts from RPGs (**Figure 2H**). Indeed, compared to mRNA levels, where C6/C16-induced changes are confined (with the exception of *RPL22L1*) to a decrease in expression of WDR5-bound RPGs, translational effects are not, and some of the most pronounced TE changes occur at non-WDR5 ribosomal protein target genes. Thus, beyond what we have been able to infer from previous studies, WINi causes a widespread reduction in the ability of MLLr cells to efficiently translate mRNAs connected to almost every aspect of protein synthesis and homeostasis.

Impact of WINi on the ribosome inventory of MLLr cancer cells

Based on the finding that WDR5 controls expression of half the RPGs, we speculated that WINi induce a ribosome subunit imbalance that leads to induction of p53 (Aho et al., 2019a). It is also possible, however, that quality control mechanisms deplete the entire inventory of ribosomal proteins during prolonged WIN site blockade. To distinguish between these possibilities, we tracked changes in ribosomal protein levels at two timepoints: 24 hours, when there is no overt cellular response to WIN site inhibition, and 72 hours, when cell proliferation begins to be inhibited (Aho et al., 2019a). The abundance of ribosomal proteins allows for the use of label-free quantitative mass spectrometry [LFQMS; (Cox et al, 2014)] in whole cell lysates to feasibly track ribosome protein levels, while also providing insight into other changes in protein levels promoted by WIN site inhibitor.

In this analysis, we tracked ~3,200 proteins at each timepoint (**Figure 3A** and **Figure 3—source data 1**), ~850 of which are significantly altered by C16 treatment. Consistent with the subtle effects of WINi on mRNA abundance and TE, most differences in protein levels triggered by C16 are less than two-fold

in magnitude (**Figure 3B** and **3C**). At 24 hours, ~90% of the proteins that change in response to C16 score as increased, whereas by 72 hours this number drops to ~60% (**Figure 3A**). Most instances of increased protein levels are transient—fewer than one third of these proteins are still induced at day three (**Figure 3D**)—whereas a majority of the proteins decreased at day one are also decreased at day three. Enrichment analysis (**Figure 3—figure supplement 1A** and **Figure 3—source data 2**) reveals that proteins induced at 24 hours are modestly enriched in those connected to exocytosis and leukocyte activation, as well as mTORC1 signaling and MYC. By 72 hours, we see induction of proteins linked to glycolysis and fatty acid metabolism, as well as apoptosis. Additionally, manual curation reveals that the number of induced p53 target proteins increases over time: 13 are induced at 24 hours, compared to 24 at the three day point (**Figure 3E**). Commensurate with the onset of a functional response to WINi, therefore, is a modest expansion in the apparent impact of p53 on the proteome, as well as the emergence of apoptotic response indicators.

Not surprisingly, proteins that are reduced in abundance at 24 hours are significantly enriched in those linked to the ribosome (**Figure 3—figure supplement 1B**). This enrichment becomes stronger at 72 hours. We also observe, at 72 hours, suppression of proteins linked to MYC and E2F targets, as well as mTORC1 signaling. In terms of ribosome components, this analysis reveals a progressive decline in the ribosomal protein inventory. Going from 24 to 72 hours, there is an increase in the number of impacted ribosomal subunits as well as in the magnitude of their suppression (**Figure 3F**), and eventually almost all ribosomal subunits are in deficit, regardless of whether or not they are encoded by a WDR5-bound gene (**Figure 3G**). Interestingly, RPL22L1 is the most strongly suppressed protein at 72 hours (**Figure 3C**), with its levels reduced by an order of magnitude after three days of C16 treatment. In sum, this analysis reveals that changes in ribosomal protein levels predicted from our transcriptomic studies manifest in reduced expression of ribosome components. Contrary to our earlier idea that WINi promote ribosome subunit imbalance, however, these data support a simpler model in which these inhibitors ultimately induce attrition of the majority of ribosomal proteins.

A loss of function screen for modulators of the response to WINi

Next, we conducted a loss of function screen to identify genes that modulate the response of MLLr cells to WINi (**Figure 4A**). First, we carried out a screen using the GeCKOv.2 sgRNA library (Joung et al, 2017), which targets ~19,000 genes with six sgRNAs each, as well as ~1,200 miRNAs (four sgRNAs each). After transducing the library into MV4;11 cells expressing Cas9, we treated for two weeks with 2 μ M C6, during which time rapidly growing cells emerged within the transduced population (**Figure 4—figure supplement 1A**). We harvested genomic DNA, performed next-generation sequencing, and compared sgRNA representation before and after C6 treatment. We inventoried genes with significant enrichment/depletion in corresponding sgRNAs in the treated population, removed pan-essential genes (Tsherniak et al, 2017), and created a custom library in which protein-coding "hits" are targeted by four different sgRNAs (Doench et al, 2016). The smaller library was screened against C6 or C16 in Cas9-expressing MV4;11 cells. This two-tiered approach allowed us to efficiently screen two different WIN site inhibitors and to identify high-confidence hits that are validated with up to 10 distinct sgRNAs.

Although the first tier did not discriminate between genes that modulate fitness and those that modulate WINi response, several interesting observations emerged. Guide RNAs corresponding to ~70 genes were enriched and ~675 were depleted (**Figure 4B**), most of the latter of which are pan-essential (**Figure 4—source data 1**). Satisfyingly, *TP53* is the most highly enriched gene in the screen (**Figure 4B** and **Figure 4—figure supplement 1B**). *CDKN2A* also scored as highly enriched in the initial screen (**Figure 4B**)—specifically those sgRNAs targeting p14^{ARF} (**Figure 4—figure supplement 1C–1D**), an inhibitor of the p53 ubiquitin ligase MDM2 (Sherr, 2001). Further support for the importance of p53 is evidenced by network analysis (Chang & Xia, 2023) of the 27 miRNAs flagged as enriched (**Figure 4—source data 1**), which display connections to p53 (**Figure 4—figure supplement 1E**). Finally, we note that the second most highly-enriched gene in the first tier encodes a ribosomal protein: *RPL22* (**Figure 4B** and **Figure 4—figure supplement 1F**). Because of the strong enrichment of sgRNAs against *RPL22* and *TP53*, we removed both genes from the second tier screen.

The second tier screen (**Figure 4—figure supplement 1G** and **Figure 4—source data 2**) revealed that the response of MV4;11 cells to C6 and C16 is very similar, both in terms of the enriched/depleted genes and their rankings (**Figure 4C**). A majority of genes that modulate the response to C6 similarly modulate the response to C16 (**Figure 4D**). For most of the depleted genes that appear specific to one WINi, similar depletion is observed with the other WIN site inhibitor, but is generally just over the FDR cutoff (**Figure 4—figure supplement 1H**). But for C6-specific enriched genes we see that most have high FDR values in the C16 samples, arguing that the earlier generation compound has expanded, off-target, activities. Gene ontology (GO) enrichment analysis of the 57 common genes emerging from the screen revealed enrichment in four overlapping categories connected to p53 signaling, apoptosis, the DNA damage response, and histone modifications (**Figure 4E** and **Figure 4—figure supplement 1I**). The representation of genes connected to p53 and to apoptosis reinforces the importance of p53-mediated cell death to the response of MLLr cells to WINi. We observe, for example, that loss of function of the p53 antagonist and ubiquitin ligase MUL1 (Jung et al, 2011), increases sensitivity to C6/C16, whereas loss of canonical p53 effectors NOXA, BAX, and ZMAT3 is associated with a decrease in response. The DNA damage response (DDR) category overlaps with that of p53 but is nonetheless distinct and includes genes encoding the ATM and CHK2 kinases (Blackford & Jackson, 2017) and the FOXM1 transcription factor that activates DDR gene expression networks (Zona et al, 2014). This category also includes two depleted genes, encoding FBXL5—which antagonizes ATM signaling (Chen et al, 2014)—and DYRK1A—a kinase involved in the DDR (Laham et al, 2021), DREAM complex activation (Litovchick et al, 2011), and RPG transcription (Di Vona et al, 2015). Consistent with representation of DDR genes in hits from the screen, C16 induces the DNA damage marker γ -H2AX in MV4;11 cells (**Figure 4—figure supplement 1J** and **Figure 4—source data 3**), implying that DNA damage, and the ability to mount a DDR, are part of the mechanism of action of WINi in this setting.

A majority of genes in the histone modification category, when disrupted, blunt the response to both WINi (**Figure 4E**). These genes include those encoding the H3K27 demethylase KMD6A (Lan et al, 2007), the MLL/SET protein KMT2D [MLL2; (Shinsky et al, 2015)], and ARID4A—a component of the mSin3/HDAC1 co-repressor complex (Lai et al, 2001). The most conspicuous sensitizing gene in this group is BRD3, a member of the BET family of proteins that includes BRD2 and BRD4 (Eischer et al,

2023). Interestingly, although BRD4 was not included in the second screen tier as it is pan essential, BRD2 was not included because it was not significantly enriched/depleted in the first tier (**Figure 4—source data 1**), revealing that the actions of BRD3 in modulating response to WINi are not shared with all family members. Further supporting the importance of BRD3 to the response, we note that SPOP, which targets BET family proteins for proteasomal destruction (Janouskova et al, 2017), is one of the most significantly enriched hits from the screen (**Figure 4E**).

Collectively, these findings demonstrate functional involvement of the ribosomal protein RPL22 in the response to WINi, confirm the importance of the p53 network to robust inhibition of MLLr cell growth by these agents, and reveal a role for DNA damage in the response to WIN site inhibitor. These findings also identify a number of candidate predictive biomarkers of response that can be further interrogated for their value as patient-selection criteria.

Identification of agents that synergize with WINi in MLLr cells

Given the ways in which resistance to WINi can arise (**Figure 4**), the most efficacious application of these agents will likely be in combination with other therapies. We therefore asked whether C16 synergizes with 11 approved or targeted agents. Several of the agents were chosen based on the results of our screen. Harmine—an inhibitor of the DYRK1A kinase (Gockler et al, 2009)—and the BET family inhibitor mivebresib (McDaniel et al, 2017) each target the product of sensitizing genes, whereas venetoclax inhibits BCL-2 (Souers et al, 2013)—an inhibitor of BAX, which scored as a resistance gene. We also tested agents connected to the DDR [etoposide, olaparib, and the ATR inhibitor VE821; (Charrier et al, 2011)], protein synthesis and homeostasis (alvespimycin and rapamycin), and p53 (nutlin-3a). Due to the enrichment of PRMT5 substrates in our translational profiling (**Figure 2—figure supplement 1F**), we queried the PRMT5 inhibitor pemrametostat (Chan-Penebre et al, 2015). And because DOT1L inhibitors suppress not only classic MLL fusion target genes (Bernt & Armstrong, 2011; Daigle et al, 2011) but also RPGs (Lenard et al, 2020), we tested for synergy with the DOT1L inhibitor pinometostat (Daigle et al., 2011). We treated MV4;11 cells with a dose matrix spanning 49 unique dose combinations and quantified synergy δ -scores using the Zero Interaction Potency (ZIP) model (Yadav et al, 2015) (**Figure 5A-B, Figure 5—figure supplement 1A and 1B, and Figure 5—source data 1**).

In MV4;11 cells, we observe synergy with mivebresib, pemrametostat, pinometostat, etoposide, harmine, and venetoclax. Within this group are three agents selected based on sensitizing targets from the CRISPR screen, providing additional support for the role of DYRK1A, BCL-2/BAX, and BRD3 in the responsiveness to WINi. Of the three agents connected to the DDR, only etoposide displays significant synergy. Agents that target protein synthesis and homeostasis yield mixed results—we observe potent antagonism with the mTOR inhibitor (Raught et al, 2001) rapamycin (peak δ -score -16), while the HSP90 inhibitor alvespimycin (Schnur et al, 1995) is either antagonistic or synergistic, depending on dose (**Figure 5A**). Finally, we note that—of the agents displaying synergy—four are particularly strong (peak δ -scores >10) and observed at agent doses consistent with on-target activity (**Figure 5—figure supplement 1B**), suggesting that mivebresib, pemrametostat, pinometostat, and venetoclax should be prioritized for in vivo testing. Focusing on these agents is further justified by our finding that all four are synergistic with C16 in MOLM13 cells (**Figure 5C–D and Figure 5—figure supplement 2A and 2B**).

To understand how combination with another agent impacts the response to WINi, we profiled MV4;11 cells treated for forty-eight hours with C16 and mivebresib, either as single agents or in combination, at concentrations that yield peak synergy between them (100 nM C16 and 2.5 nM mivebresib). By RNA-Seq (**Figure 5—source data 2**), it is clear that the functional synergy between C16 and mivebresib is apparent at the transcript level, with more than 6,200 gene expression changes in the combination treatment, compared to less than 1,800 for C16 and 2,700 for mivebresib (**Figure 5E**). Notable are the very distinct transcriptional profiles induced by each agent alone, with fewer than 200 shared gene expression changes in each direction (**Figure 5F**). The impact on RPG expression of both agents is additive (**Figure 5—figure supplement 3A**), but in general we find that the combination of C16 and mivebresib dysregulates similar categories of genes for each agent alone, but with substantially more genes in each category (**Figure 5—source data 3**). This is clear for genes linked to translation (**Figure 5G**), to p53 (**Figure 5—figure supplement 3B**), and to the induction of apoptosis (**Figure 5H**). Thus, although further investigation is needed, this analysis is consistent with the idea that synergy between C16 and mivebresib results from alterations in the expression of distinct but complementary sets of genes that ultimately conspire to augment induction of p53.

WINi inactivate MDM4 in an RPL22-dependent manner

Despite the importance of p53 in the response to WINi, WIN site inhibitors cause only a slight increase, if any, in p53 levels [**Figure 6—figure supplement 1A**, **Figure 6—source data 1** and (Aho et al., 2019a)]. Interestingly, inactivation or loss of *RPL22* in cancer is associated with increased expression of *RPL22L1* and inclusion of exon 6 in MDM4 (Ghandi et al, 2019), an event that promotes MDM4 expression by preventing formation of a "short" MDM4 mRNA isoform (MDM4s) that is destroyed by nonsense-mediated decay (Rallapalli et al, 1999). MDM4 is intriguing because it can suppress p53 without altering its stability (Francoz et al, 2006). It is also intriguing because skipping of exon 6 in the *MDM4* mRNA is stimulated by ZMAT3 (Biegging-Rolett et al., 2020; Muys et al, 2021) and antagonized by RPL22L1 (Larionova et al, 2022)—two genes that are oppositely regulated by WINi. We therefore asked if WINi induce changes in the levels of mRNA splice isoforms and if this includes MDM4.

RNA-Seq data (**Figure 1**) were interrogated for alternative splicing events (Shen et al, 2014). At an FDR < 0.05 and a threshold of $\geq 5\%$ change in exon inclusion ($\Delta\psi$), C6 and C16 each result in changes in $\sim 1,000$ differentially-spliced mRNAs (**Figure 6—figure supplement 1B**), ~ 250 of which are shared between the two inhibitors (**Figure 6A**). Many of these changes reflect events with low read counts or at minor splice sites (**Figure 6—source data 2**), representative examples of which are presented in **Figure 6—figure supplement 1C–D**. That said, WINi clearly promote accumulation of *MDM4* transcripts in which exon 6 is skipped (**Figure 6B**). We also observe splicing changes at *RPL22L1* itself (**Figure 6—figure supplement 1E**), where WINi leads to the depletion of transcripts in which exon 2 is spliced to a distal 3' acceptor site in exon 3. This splicing event encodes the RPL22L1a isoform that is incorporated into ribosomes (Larionova et al., 2022). Splicing to the proximal 3' acceptor site, which generates a non-ribosomal RPL22L1b isoform that modulates splicing, is insensitive to WINi. We confirmed the impact of C16 on *MDM4* and *RPL22L1* splice isoforms by semi-quantitative RT-PCR (**Figure 6—figure supplement 1F** and **Figure 6—source data 3**) and quantitative RT-PCR (**Figure 6**

—**figure supplement 1G**). Based on these observations, we conclude that treatment of MLLr cells with WINi promotes the selective loss of transcripts encoding RPL22L1a and MDM4.

The association of *RPL22* loss with increased expression of *RPL22L1* and inclusion of exon 6 in *MDM4* (Ghandi et al., 2019) prompted us to ask how *RPL22* contributes to the response of MLLr cells to WINi. Knockout (KO) of *RPL22* (**Figure 6—figure supplement 2A** and **Figure 6—source data 4**) decreases the sensitivity of MV4;11 and MOLM13 cells to C16 by three- to five-fold compared to non-targeted (NT) control cells (**Figure 6C** and **Figure 6—figure supplement 2B**), as well as attenuating the modest induction of p53 protein observed in the MV4;11 line (**Figure 6D** and **Figure 6—source data 5**). The response of relatively insensitive (p53-null) K562 cells, in contrast, is unaffected by *RPL22* disruption (**Figure 6C**). RNA-Seq analysis (**Figure 6—figure supplement 2C–D** and **Figure 6—source data 6**) reveals that disruption of *RPL22* does not impact the effect of WINi on WDR5-bound RPGs (**Figure 6—figure supplement 2E**), but it does block the effects of C16 on expression of *RPL22L1* and *ZMAT3* (**Figure 6—figure supplement 2D**), as well as tempering its ability to suppress genes connected to the cell cycle, mTORC1 signaling, and MYC (**Figure 6—figure supplement 2F** and **Figure 6—source data 7**). Notably, *RPL22* loss also impairs induction of genes involved in p53 signaling (**Figure 6E** and **Figure 6—figure supplement 2G**). We also observe that mitochondrial RPGs are induced by WINi uniquely in *RPL22*-null cells (**Figure 6—figure supplement 2H**). We conclude that RPL22 is needed for a majority of the characteristic responses of MLLr cells to WINi, including activation of p53.

Finally, we asked if *RPL22* knockout alters patterns of alternative splicing induced by WINi. Thousands of differences were detected in splice isoforms between the various pairwise comparisons (**Figure 6—source data 8**). In general, *RPL22KO* cells show fewer C16-induced changes in alternative splicing patterns than NT cells (**Figure 6—figure supplement 3A**). As we observed above, a majority of the changes reflect events with low read counts or at minor splice sites, with two notable exceptions: *MDM4* and *RPL22L1*. In the absence of WINi, disruption of *RPL22* promotes exon 6 retention in *MDM4* (**Figure 6—figure supplement 3B**) and induces expression of the mRNA splice isoform encoding RPL22La (**Figure 6—figure supplement 3C**). In the presence of C16, disruption of *RPL22* mitigates skipping of exon 6 in *MDM4* (**Figure 6F**) and largely blocks suppression of the RPL22L1a-encoding mRNA isoform (**Figure 6—figure supplement 3C**). Importantly, these changes in mRNA isoforms manifest at the protein level (**Figure 6G** and **Figure 6—source data 9**) as we observe that both MDM4 and RPL22L1 protein expression is suppressed by C16, that RPL22L1 is induced by RPL22 disruption, and that loss of RPL22 blocks a majority of the ability of C16 to reduce expression of the MDM4 and RPL22L1 proteins. We also note that loss of RPL22 blocks induction of the p53 target, p21. Taken together, these data demonstrate that RPL22 loss can cause the induction of RPL22L1 and inclusion of exon 6 in *MDM4* observed in cancer (Ghandi et al., 2019), and reveal that splicing-driven suppression of *MDM4* is a major mechanism through which WINi activate p53 in MLLr cells.

Discussion

Here, we describe an integrated multiomic approach to characterize the mechanism of action of WDR5 WIN site inhibitors in MLL-rearranged cancer cells. By combining transcriptional, translational, and proteomic profiling with genome-wide loss of function screens, we demonstrate the broad impact of WINi on the ribosomal protein complement and translational capacity of MLLr cells, reveal the importance of multiple arms of the p53 response pathway in cellular inhibition, and uncover a role for alternative splicing of MDM4 in activating p53 in this setting. Collectively, these data cast WIN site inhibitors as a novel ribosome-directed anti-cancer therapy and provide insight into patient selection criteria, mechanisms of resistance, and strategies to improve WINi efficacy in the clinic.

The primary targets of WINi, we propose, are the cohort of ~40 RPGs that are bound by WDR5 in all cell types examined (Aho et al., 2019a; Bryan et al., 2020; Florian et al., 2022). These RPGs are rapidly transcriptionally suppressed in response to WIN site blockade (Aho et al., 2019a; Bryan et al., 2020; Florian et al., 2022) or WDR5 degradation (Siladi et al., 2022), and show sustained suppression at the mRNA level. These same RPGs are suppressed by disruption of the MYC–WDR5 interaction (Thomas et al., 2019), implying that the function of WDR5 at these genes is to recruit MYC, a prominent target of MLL-fusion oncoproteins (Ahmadi et al, 2021). Previously, we posited that suppression of half the RPGs would lead to a ribosomal subunit imbalance (Aho et al., 2019a), but our analysis shows that WINi deplete the entire ribosomal inventory. Part of this depletion is driven by decreased translation of ribosomal mRNAs, although it is also possible that ubiquitin-mediated quality control mechanisms or ribophagy (Zhao et al, 2022) degrade ribosomal proteins under these conditions.

The effects of WINi on ribosomal protein levels are extensive in terms of the number of impacted subunits, but not the magnitude of change, which caps at around a 30% decrease by 72 hours. This cap could be set by the maximal contribution of MYC–WDR5 to the expression of target RPGs, which is two-fold as determined by genetic disruption of the MYC–WDR5 interaction (Thomas et al., 2019), degradation of WDR5 (Siladi et al., 2022), or WIN site blockade. Although modest, it should be noted that a 30% decrease in ribosomal protein levels corresponds to a loss of up to three million ribosomes per cell (Shore & Albert, 2022), and in that light it is not surprising that WINi result in reduced translational efficiencies of about half of all actively-translated mRNAs. Unlike perturbations such as ER stress (Advani & Ivanov, 2019), WINi does not promote preferential translation of stress-responsive mRNAs, although there is some specificity in terms of the translational consequences. Messenger RNAs carrying 5'TOP motifs, for example, are spared from the full translational impact of C6/C16, and we see distinct biological clustering of mRNAs with decreased translation efficiency. Whether these patterns are intrinsic to WINi, or a general response of MV4;11 cells to translational stress, remains to be determined. Overall, we conclude that WINi do not trigger extensive translational reprogramming, but rather act to induce a widespread yet restrained translational choke.

Downstream of ribosomal protein attrition, we observe several responses to WINi that are shared with rRNA inhibitors. Induction of DNA damage, as measured by accumulation of γ -H2A.X, is also seen with the RNA polymerase I inhibitor CX-5461 (El Hassouni et al, 2019; Quin et al, 2016), and this has been proposed to be an important and exploitable attribute in terms of its future clinical application (Sanij et

al, 2020). The fact that not all rRNA inhibitors induce DNA damage [e.g., (Peltonen et al., 2014)], as well as the action of CX-5461 as a G-quadruplex (G4) stabilizer (Xu et al, 2017), has cast doubt on the contribution of rRNA inhibition versus G4 stabilization to the DNA damage component of CX-5461 activity. But the demonstration that C6/C16 induce γ -H2A.X and depend on components of the DDR for full activity, together with a growing appreciation of the susceptibility of rDNA to damage and of the nucleolus as a hub for the DDR (Xuan et al, 2021)—suggests that DNA damage and the response to it may be an inherent part of the mechanism of action of ribosome-directed anti-cancer strategies.

Activation of p53, and p53-dependent cellular inhibition, is another point of convergence of WDR5 and rRNA inhibitors. Not only do we detect activation of p53 target genes in response to WIN site blockade, but we observe synergistic activation of p53 target genes with the BET bromodomain inhibitor mivebresib and suppression of p53 targets upon deletion of *RPL22*; both of which correlate with cellular sensitivity. We also recover multiple components of the p53 signaling pathway as "resistance" genes in our CRISPR screens, including p53 itself and the splicing factor ZMAT3. Inhibition of rRNA synthesis is thought to activate p53 by generating excess ribosomal proteins that bind to and inactivate MDM2 (Pfister, 2019). It is likely that inhibition of MDM2 contributes to p53 activation in response to C6/C16, as we see a modest increase in p53 levels in MV4;11 cells exposed to WINi, and find that loss of the MDM2 inhibitor p14^{ARF} renders MV4;11 cells less sensitive to C6/C16. Here, however, we also find that there is a second route of p53 activation at work, in which WINi promote accumulation of alternatively spliced isoforms of *MDM4* mRNA in which exon 6 is skipped, driving down MDM4 protein levels. Because MDM4 inhibits p53 via proteolysis-independent mechanisms (Francoz et al., 2006), these findings explain how WIN site inhibitors can induce a robust p53 target gene signature in the absence of frank induction of p53 protein. They also point to a dominant role of the MDM4–p53 axis in mediating the response of MLLr cells to WIN site blockade. Whether rRNA inhibition triggers p53 activation by a similar mechanism has, to our knowledge, yet to be reported.

In considering the mechanism through which WINi inactivate MDM4, it is possible that the balance of RPL22L1 and ZMAT3, which are oppositely regulated in response to WIN site inhibition, governs the extent of MDM4 exon 6 inclusion. ZMAT3 is induced in response to p53 activation and promotes skipping of exon 6 in MDM4 (Biegging-Rolett et al., 2020). RPL22L1, in contrast, which is potently suppressed by WIN site inhibitor, promotes exon 6 inclusion (Larionova et al., 2022). Any process that tips the balance in favor of ZMAT3, therefore, would be expected to inhibit MDM4, activate p53, and initiate a feed-forward mechanism that drives ZMAT3 expression and fortifies p53 induction. Induction of ZMAT3 alone should be sufficient to trigger this circuit, but the conspicuous suppression of RPL22L1 by WIN site inhibitor suggests that this may also contribute to the response. Paradoxically, the isoform of RPL22L1 that is suppressed by WIN site blockade, RPL22L1a, is linked in glioblastoma cells to ribosome function, not splicing (Larionova et al., 2022), while the splicing-relevant RPL22L1b isoform is resistant to WINi. One possibility is that, despite its recurrence and prominence, suppression of RPL22L1a by C6/C16 does not contribute to MDM4 suppression, and induction of ZMAT3 is the critical driving factor. Alternatively, RPL22L1a may indeed act to control splicing in MLLr cells, in contrast to what has been reported in glioblastoma. Further investigation is required.

The RPL22–RPL22L1–MDM4 nexus we encountered has been inferred by genome-wide studies of the Cancer Cell Line Encyclopedia [CCLE; (Ghandi et al., 2019)], and our work here demonstrates that loss of *RPL22* causes induction of RPL22L1 and promotes inclusion of exon 6 in MDM4. We have no evidence that RPL22 itself plays a role in the response to WINi in otherwise unperturbed MLLr cells. Rather, we suggest that its recovery as a resistance gene in our CRISPR screen is tied to its ability to suppress *RPL22L1* expression (O'Leary et al, 2013), and the ectopic effect of its deletion on preventing WINi-induced RPL22L1a decline. That said, RPL22 status is likely to be highly relevant in terms of patient selection criteria. *RPL22* is frequently inactivated or deleted in primary cancer samples (Ghandi et al., 2019; Goudarzi & Lindstrom, 2016; Kandath et al, 2013), as well as 7% of lines in the CCLE (Cao et al, 2017). Unlike other RPGs, mutation or deletion of *RPL22* is not associated with mutational inactivation of p53, and indeed there is a strong tendency for wild-type p53 to be retained in *RPL22* mutant/deletion lines (Cao et al., 2017; Ghandi et al., 2019). In practical terms, therefore, cancers that retain wild-type p53 but otherwise are mutated/deleted for *RPL22*, or overexpress *RPL22L1*, would not be expected to robustly respond to WIN site inhibitor.

Although p53 is important for the action of WINi in MLLr cells, there are likely other stress response mechanisms that mediate cellular inhibition by these agents. A number of p53-independent nucleolar stress responses have been identified [e.g., (Boglev et al, 2013; Jayaraman et al, 2017; Pfister et al, 2015)], including those involving DNA damage response pathways that delay S-phase progression and induce a G2 cell cycle arrest (Sanij et al., 2020). Conversely, we might also expect cells to be able to mount protective responses to WIN site blockade. In this regard, it is curious that four resistance genes identified in our CRISPR screen—UBA6, BIRC6, KCMF1, and UBR4—encode members of a newly-identified BIRC6 ubiquitin-ligase complex (Cervia et al, 2023), the function of which is to prevent aberrant activation of the integrated stress response (ISR). The ISR is a central regulator of protein homeostasis (Costa-Mattioli & Walter, 2020) that drives protective translational reprogramming in response to multiple cellular stresses. There is no indication that the ISR is activated by WINi; indeed the master regulator of ISR, ATF4, is suppressed by C6/C16 at the mRNA and translational levels. But the finding that loss of all four members of the BIRC6 complex blunts the response to WINi implies that ISR activation can be a mechanism through which cells evade the full impact of these agents.

As with most monotherapies, future single agent WINi treatment paradigms are likely to encounter resistance, either by activation of protective responses such as those proposed above, or by mutations in one or more of the resistance genes recovered in our CRISPR screen. Identification of agents that can be used in combination with WINi to increase cancer cell inhibition is thus crucial. Our relatively limited synergy screening identified a number of combinations that should be prioritized for in vivo testing. We found that WINi act synergistically with the BCL-2 inhibitor venetoclax (Souers et al., 2013). This is mechanistically rationalized by our recovery of BAX as a resistance gene, and is noteworthy because venetoclax is an approved therapy for several blood-borne cancers. We also identified notable synergies with experimental agents targeting BET bromodomain family members, DOT1L, and PRMT5. The combination with mivebresib is rationalized based on identification of BRD3 as a sensitizing gene, and likely results from the ability of C16 and mivebresib to inhibit distinct sets of genes connected to translation, the impact of which is to enhance p53 induction. BET bromodomain inhibitors have

struggled in clinical trials due to dose-limiting toxicities (Shorstova et al, 2021), but their combination with WINi could form the basis of a more effective therapy with less side effects. Moreover, given the mechanism the underlying synergy between C16 and BET inhibitors, we would expect this combination to be effective in other wild-type p53 cancer settings where WINi are active, such as neuroblastoma (Bryan et al., 2020) and rhabdoid tumors (Florian et al., 2022). Expanded synergy screening is needed to identify and understand the full spectrum of combination approaches that could be used to ultimately enhance and extend the clinical utility of WIN site inhibitors.

Figure legends and index

Figure 1. Impact of WINi on the transcriptome of MLLr cancer cells. (A) Chemical structures of C6 and C16. (B) Crystal structures of C6 or C16 bound to the WIN Site of WDR5 with electrostatic surfaces mapped [PDB IDs: 6E23 (Aho et al., 2019a); 6UCS (Tian et al., 2020)]. The image shows a close-up view of the WIN site. (C) Superimposed WIN site-binding conformations of C6 (green) and C16 (blue). (D) Transcript levels as determined by QuantiGene™ analysis of representative WDR5-bound (color) or non-bound (grayscale) ribosomal protein genes in MV4;11 cells treated with a serial dilution range of either C6 (left) or C16 (right) and relative to DMSO-treated cells ($n = 2-3$; Mean \pm SEM). Vertical dashed line indicates either 2 μ M C6 (left) or 100 nM C16 (right). (E) Number of genes with significantly (FDR < 0.05) altered transcript levels following treatment of MV4;11 cells with C6 (2 μ M) or C16 (100 nM) for 48 hours, as determined by RNA-Seq ($n = 3$). See **Figure 1—source data 1** for complete output of RNA-Seq analysis. (F) Comparison of gene expression changes elicited by C6 (x-axis) and C16 (y-axis), represented as Log₂ fold change (FC) compared to DMSO. WDR5-bound genes are colored red. Locations of *RPL22L1* and *ZMAT3* are indicated. (G) Overlap of genes with decreased (left) or increased (right) transcript levels in MV4;11 cells treated with C6 or C16. (H) Gene Set Enrichment Analysis (GSEA) showing the distribution of genes suppressed in MV4;11 cells in response to C6 (left) or C16 (right) against the list of all genes bound by WDR5 in those cells (Aho et al., 2019a). NES = normalized enrichment score. (I) Enrichment analysis of genes suppressed (left) or induced (right) by C6 or C16 in MV4;11 cells. KEGG and Hallmark.MSigDB pathways are shown. Fold enrichment of indicated pathways is presented on the x-axis, the number of genes is shown in italics in each bar, and colors represent $-\text{Log}_{10}$ FDR. See **Figure 1—source data 2** for additional GSEA (Hallmark) and ORA (Hallmark) analyses of differentially expressed genes. (J) Transcript level changes in WDR5-bound (left) and non-bound (right) RPGs elicited by C6 (top) or C16 (bottom).

Figure 1—figure supplement 1. Transcript changes elicited by WINi in MLLr cancer cells. (A) Crystal structures of C6 or C16 bound to the WIN Site of WDR5 with electrostatic surfaces mapped [PDB IDs: 6E23 (Aho et al., 2019a); 6UCS (Tian et al., 2020)]. (B) Viabilities of MV4;11 cells treated with a serial dilution range of either C6 (left) or C16 (right) for 72 hours, relative to viability of DMSO-treated cells ($n = 3$; Mean \pm SEM). (C) As in (B) but for MOLM13 cells. (D) Transcript levels as determined by QuantiGene™ analysis of representative WDR5-bound (color) or non-bound (grayscale) ribosomal protein genes in MOLM13 cells treated with a serial dilution range of either C6 (left) or C16 (right) and relative to DMSO-treated cells ($n = 3$; Mean \pm SEM). Vertical dashed line indicates either 2 μ M C6 (left) or 100 nM C16 (right). (E) Transformed z-scores of genes with significantly altered transcript levels (RNA-Seq) in MV4;11 cells treated with either C6 (2 μ M) or C16 (100 nM) for 48 hours, compared to DMSO-treatment. (F) Volcano plots, showing transcript level alterations in MV4;11 cells treated 48 hours with 2 μ M C6 (left) or 100 nM C16 (right) compared to DMSO ($n = 3$; red indicates FDR < 0.05). (G) Dispersion plot describing the variance in gene expression for the RNA-seq data in a previous study (left) and this study (right).

Figure 1—figure supplement 2. Impact of WINi on *RPL22L1* and p53 target gene expression. (A) Venn diagram, showing the overlap of consensus p53 target genes (Fischer, 2017) with genes significantly induced by C6 or C16 in MV4;11 cells. (B) Graph showing the change in expression of the

91 common genes in (A) elicited by WIN site inhibitor (WINi) C6 (red) or C16 (blue) in MV4;11 cells, compared to DMSO. (C) Changes in expression (and FDR) of *RPL22L1* elicited in response to C6 (red) or C16 (blue) treatment of K562 leukemia cells (Aho et al., 2019a) or five rhabdoid tumor cell lines [TTC642, KYM-1, G401, TM87-16, and TTC549; (Florian et al., 2022)].

Figure 1—source data 1. Output of RNA-Seq analysis of MV4;11 cells treated with C6/C16.

Figure 1—source data 2. GSEA Hallmark and Over Representation Analysis (ORA) Hallmark enrichment analysis of differentially expressed genes in RNA-Seq.

Figure 2. Impact of WINi on the translome of MLLr cancer cells. (A) Volcano plots depicting alterations in translation efficiency (TE) induced by 48 hour treatment of MV4;11 cells with either 2 μ M C6 (left) or 100 nM C16 (right) compared to DMSO ($n = 2$; Red indicates $FDR < 0.05$ and $\text{Log}_2 \text{FC} > 0.25$), as determined by Ribo-Seq. (B) Number of mRNAs with significantly ($FDR < 0.05$ and $\text{Log}_2 \text{FC} > 0.25$) altered TE levels following treatment of MV4;11 cells with C6 (2 μ M) or C16 (100 nM) for 48 hours. See **Figure 2—source data 1** for complete output of Ribo-Seq analysis. (C) Overlap of mRNAs with significantly decreased TE in response to C6- or C16-treatment. (D) Translation efficiencies (TE) of mRNAs in DMSO-treated MV4;11 cells plotted against translation efficiencies of mRNAs in cells treated with either C6 (left) or C16 (right). Red indicates mRNAs with significantly altered translation efficiencies following inhibitor treatment ($FDR < 0.05$ and $\text{Log}_2 \text{FC} > 0.25$). (E) Numbers of differentially-translated mRNAs (ΔTE) in each quartile of genes (stratified by TE in DMSO) in cells treated with C6 (left) or C16 (right). (F) Enrichment analysis of common mRNAs suppressed by C6/C16 at the mRNA (blue) and translational (red; TE) level in MV4;11 cells. Hallmark.MSigDB pathways are shown. The x-axis indicates the number of suppressed genes in each category; the italic numbers are the corresponding FDR. See **Figure 2—source data 2** for the full Hallmark.MSigDB analysis, as well as for Reactome and KEGG pathways. (G) Enrichment analysis of mRNAs suppressed translationally by C6/C16 but with no significant changes in mRNA levels. Gene Ontology (GO) Biological Process (BP) and Molecular Function (MF) categories are shown, as well as KEGG pathways. The x-axis displays $-\text{Log}_{10} \text{FDR}$; the number of mRNAs is shown in italics in each bar. See **Figure 2—source data 3** for extended enrichment analyses, broken down by TE and mRNA direction changes. (H) TE changes in WDR5-bound (left) and non-bound (right) RPGs elicited by C6 (top) or C16 (bottom).

Figure 2—figure supplement 1. WINi suppress translation. (A) Distribution of ribosome protected fragment (RPF) lengths in each Ribo-Seq sample/replicate. The length distribution of RPF in mammalian Ribo-Seq experiments typically peaks at 30–31 nucleotides. (B) Proportion of RPFs mapping to the coding sequence (CDS) or 5' or 3' untranslated regions (UTR) of transcripts. Color of dots is the same as in (A). (C) Proportion of RPFs mapping to each reading frame in the 5' UTR (left), the CDS (middle), and the 3' UTR. Color of dots is the same as in (A). (D) Magnitudes of significant TE alterations of mRNAs in each quartile (stratified by TE in DMSO) in cells treated with C6 (left) or C16 (right). Color dots represent individual genes. Bottom, middle, and top horizontal lines of each box represent first, second, and third quartiles, respectively. Vertical lines extend to data points within 1.5-fold of the interquartile range. Black dots represent values beyond 1.5-fold of the inter-quartile range.

(E) Changes in TE induced by C6 (left) or C16 (right) in MV4;11 cells, binned according to mRNA TOPscores (Philippe et al., 2020). Dashed lines represent the median; dotted lines indicate quartiles. Significance by t-test is indicated compared to group with TOPscore 0 to 1 (** ≤ 0.05 , *** ≤ 0.0001). (F) UpSet plot, showing the breakdown of genes encoding PRMT5 substrates (Radzisheuskaya et al., 2019) whose transcript levels and/or translation efficiencies decrease following WIN site inhibition (p -value calculated by hypergeometric test for over-representation of genes encoding PRMT5 substrates in genes with decreased translation efficiencies). (G) Overlap of C6/C16 common mRNAs with decreased abundance (RNA; blue) and those with decreased translation efficiency (TE; salmon), grouped according to the indicated Hallmark.MSigDB categories. (H) Overlap of all C6/C16 common mRNAs with altered abundance and decreased TE. (I) The top row of the heatmap displays the codon stability coefficient (CSC) for each codon (Wu et al., 2019) ranked from lowest ('Non-optimal') to highest ('Optimal'). The middle row displays enrichment of each codon in mRNAs that are decreased at both the TE and mRNA levels (RNA+TE) versus those that show a decrease in TE without an accompanying decrease in mRNA abundance (TE only). Bottom row is $-\text{Log}_{10}$ FDR.

Figure 2—figure supplement 2. WINi impair translation of mitochondrial ribosomal proteins. (A) Top: Transcript level changes in mitochondrial ribosomal protein genes elicited by C6 or C16, as indicated. Bottom: Translational efficiency (TE) changes in mitochondrial ribosomal protein genes elicited by C6 or C16. All of the mitochondrial RPGs are nuclear-encoded; none have detectable binding of WDR5.

Figure 2—source data 1. Output of Ribo-Seq analysis of MV4;11 cells treated with C6/C16.

Figure 2—source data 2. Hallmark, Reactome, and KEGG enrichment analysis of differentially translated genes in Ribo-Seq.

Figure 2—source data 3. Enrichment analysis of differentially-translated genes, broken down by mRNA level change direction.

Figure 3. Impact of WINi on the ribosome inventory of MLLr cancer cells. (A) Lysates from MV4;11 cells treated 24 or 72 hours with either 0.1% DMSO or 250 nM C16 were subjected to liquid chromatography coupled with tandem mass spectrometry and analyzed by label-free quantification (LFQMS). The table shows the number of proteins detected in DMSO and C16 samples and those with significantly altered levels at each time point ($n = 4$; adj. p -value < 0.05). See **Figure 3—source data 1** for complete output of LFQMS analysis. (B) Volcano plot, showing protein level alterations in cells treated with C16 for 24 hours (red indicates adj. p -value < 0.05). The location of RPL22L1 is indicated. (C) As in (B) but for 72 hour treatment with C16. (D) Overlap of proteins significantly increased (top) or decreased (bottom) following 24- or 72-hour C16-treatment. (E) Protein level alterations induced by C16 in consensus p53 target proteins (Fischer, 2017) at the 24 and 72 hour treatment timepoints. Those proteins only altered in abundance at 24 hours are represented as blue dots; proteins only altered at 72 hours are red; proteins altered at both timepoints are grey. (F) As in (E) but for ribosomal proteins. (G) Changes in expression of proteins encoded by WDR5-bound (left) and non-bound (right) RPGs elicited by 24 (top) or 72 (bottom) hour treatment with C16. Note that, due to the magnitude of change, $\text{Log}_2(\text{FC})$ for RPL22L1 is presented on a separate scale.

Figure 3—figure supplement 1. Enrichment analysis of proteins with altered expression in response to C16 treatment. (A) Graphs showing enrichment of proteins in GO BP (top) and Hallmark.MSigDB (bottom) pathways that are induced by C16 treatment at 24 (blue) or 72 (green) hours. The x-axis displays $-\text{Log}_{10}$ (FDR); the number of proteins in each category is given in italics. (B) Graphs showing enrichment of proteins in GO BP (top) and Hallmark.MSigDB (bottom) pathways that are suppressed by C16 treatment at 24 (red) or 72 (brown) hours. The x-axis displays $-\text{Log}_{10}$ (FDR); the number of proteins in each category is given in italics. See **Figure 3—source data 2** for output of the full enrichment analyses.

Figure 3—source data 1. Output of LFQMS analysis of MV4;11 cells treated with C16.

Figure 3—source data 2. Enrichment analysis of proteins altered in abundance by 24 or 72 hours of C16 treatment.

Figure 4. A loss of function screen for modulators of the response to WINi. (A) Two-tier screen design. In the first tier, Cas9-expressing MV4;11 cells were transduced with a genome-wide sgRNA library and treated with 2 μM C6 until a resistant cell population emerged. sgRNA representation in the pre-treatment population was compared to the post-treatment population. In the second tier, cells were transduced with a custom library of distinct sgRNAs targeting non-pan-essential "hits" from the first tier, cultured in the presence of DMSO, C6, or C16, and sgRNA representation in C6/C16-treated cultures compared to that from DMSO-treated cultures. Created with BioRender.com. (B) Volcano plot, showing gene-level changes in sgRNA representation from the first tier (orange indicates $\text{FDR} < 0.05$). Datapoints corresponding to *TP53*, *RPL22*, and *CDKN2A* are indicated. See **Figure 4—source data 1** for full output of the Tier 1 screen. (C) Comparison of gene-level changes in sgRNA representation in C6- and C16-treated populations in the second tier screen, each compared to DMSO-treated populations (red indicates $\text{FDR} < 0.05$; black indicates non-targeting control sgRNAs). See **Figure 4—source data 2** for full output of the Tier 2 screen. (D) Top: Overlap of genes from the Tier 2 screen with enriched (left) or depleted (right) sgRNAs in C6- and C16-treated MV4;11 populations, compared to the DMSO control. Bottom: Overlap of genes with enriched (left) or depleted (right) sgRNAs in the first versus second tiers of the screen. "Tier 1" contains only those genes targeted in the Tier 2 screen. "Tier 2" contains the intersection of genes with altered sgRNAs in both the C6 and C16 treatments. (E) Ranked heatmap, representing the mean gene-level Log_2 fold change (FC) of sgRNAs from the C6 and C16 treatments in the Tier 2 screen, as well as gene enrichment analysis outputs. Note that "Signal transduction by p53 class mediator" is a GO:BP term (orange); "p53" assignments (yellow) were added by manual curation.

Figure 4—figure supplement 1. Genome wide CRISPR screen identifies genes that influence response to C6/C16. (A) Tier 1 screen: Daily cell counts of MV4;11 Cas9 and MV4;11 Cas9 + GeCKOv2 (Library) populations treated with either DMSO or 2 μM C6. The two replicates of this screen are shown separately. (B) Normalized counts of each sgRNA (x-axis) in the GeCKOv.2 library targeting *TP53* in the initial transduced cells (red; not visible on this scale) and the C6-treated population (blue). Data represents means of replicates; "*" indicates $\text{FDR} < 0.05$. (C) As in (B) but for sgRNAs targeting

CDKN2A. (D) Schematic of the *CDKN2A* gene locus with indicated sites complementary to Tier 1 and Tier 2 screen sgRNAs. Red sgRNAs increase in representation in CRISPR screens. (E) miRNet 2.0 (Chang & Xia, 2023) analysis of the 27 miRNAs enriched in the Tier 1 screen produced a single significant hit corresponding to the KEGG p53 signaling pathway. The miRNAs are represented as blue boxes and target genes as red circles; the connections between them are indicated. (F) As in (B) but for sgRNAs targeting *RPL22*. (G) Volcano plots, showing gene-level changes from the Tier 2 screen in sgRNA representation in C6- (left) and C16- (right) treated populations compared to DMSO control cultures (orange indicates $FDR < 0.05$). (H) Graph depicting gene-level Log₂ FC and FDR values for genes that were flagged as C6- (squares) or C16- (circles) specific in the Tier 2 screen. (I) GO enrichment analysis of the 57 C6/C16 common genes emerging from Tier 2 of the screen. Italics represent the number of genes in each category. (J) Western blot analysis of γ -H2A.X (top) or H2A.X (bottom) levels in MV4;11 cells treated for three days with the indicated dose of C16. Etoposide ("Etop.") treatment was used as a positive control. GAPDH is a loading control. Representative images from three biological replicates shown. Raw unprocessed gel images for the data in (J) are presented in **Figure 4—source data 3**.

Figure 4—source data 1. Output of the Tier 1 screen.

Figure 4—source data 2. Output of the Tier 2 screen.

Figure 4—source data 3. Raw unprocessed gel images corresponding to Figure 4—figure supplement 1J.

Figure 5. Identification of agents that synergize with WINi in MLLr cells. (A) Peak synergy (> 0) and antagonism (< 0) ZIP Delta (δ) scores from synergy assays in which MV4;11 cells were treated for three days with 49 unique dose combinations of C16 and the indicated compound of interest ($n = 4$). See **Figure 5—source data 1** for numerical ZIP Delta analysis output. (B) Heatmaps of MV4;11 cell growth inhibition at each dose of C16 and the indicated six compounds. The remaining five combinations tested are shown in **Figure 5—figure supplement 1**. (C) As in (A) but for MOLM13 cells. See **Figure 5—source data 1** for numerical ZIP Delta analysis output. (D) As in (B) but for MOLM13 cells. The remaining five combinations tested are shown in **Figure 5—figure supplement 2**. (E) Number of genes with significantly ($FDR < 0.05$) altered transcript levels following treatment of MV4;11 cells with C16 (100 nM), mivebresib (Mibv; 2.5 nM), or the combination for 48 hours, as determined by RNA-Seq ($n = 3$). See **Figure 5—source data 2** for complete output of RNA-Seq analysis. (F) UpSet plot, showing the overlap of genes suppressed (left) or induced (right) in response to C16, mivebresib, or the combination. (G) UpSet plot, showing the breakdown of Reactome "Translation" pathway genes suppressed in response to C16, mivebresib, or the combination. (H) Enrichment of Reactome Pathways in genes with increased transcripts following treatment of MV4;11 cells with C16, mivebresib, or the combination. See **Figure 5—source data 3** for complete output of enrichment analyses.

Figure 5—figure supplement 1. C16 is synergistic with multiple agents in MV4;11 cells. (A) Heatmaps of MV4;11 cell growth inhibition at each dose of C16 and the indicated five compounds. (B) Heatmaps of δ scores from MV4;11 cells at each dose combination of C16 and the indicated agents.

Figure 5—figure supplement 2. C16 is synergistic with multiple agents in MOLM13 cells. (A) Heatmaps of MOLM13 cell growth inhibition at each dose of C16 and the indicated five compounds. **(B)** Heatmaps of δ scores from MOLM13 cells at each dose combination of C16 and the indicated agents.

Figure 5—figure supplement 3. Impact of C16 and mivebresib on RPG and p53 target gene expression. (A) Transcript level changes in WDR5-bound (left) and non-bound (right) RPGs elicited by C16 (top), mivebresib (Mivb; middle) or the combination (bottom). **(B)** Heatmap, showing significant changes in the expression of consensus p53 target genes (Fischer, 2017) induced by C16, mivebresib (Mivb; middle) or the combination (bottom) in MV4;11 cells.

Figure 5—source data 1. Peak synergy and antagonism scores for MV4:11 and MOLM13 cells treated with C16 in combination with 11 agents.

Figure 5—source data 2. Output of RNA-Seq analysis of MV4;11 cells treated with C16, mivebresib, or both.

Figure 5—source data 3. Enrichment analysis of differentially expressed genes in RNA-Seq of MV4;11 cells treated with C16, mivebresib, or both.

Figure 6. WINi inactivate MDM4 in an RPL22-dependent manner. (A) Differential alternative splicing events affected by C6/C16 treatment of MV4;11 cells were quantified by rMATS. The types of alternative splicing events are cartooned at left, and the number of significantly different events ($> 5\% \Delta\psi$; FDR < 0.05) common to C6/C16 depicted in the graph. See **Figure 6—source data 2** for output of rMATS analysis. **(B)** Sashimi plot quantifying read junctions that span exons 5–7 of *MDM4* in MV4;11 cells treated with DMSO (green) or C16 (blue). Numbers in the arcs display junction depth. The location of exons 5, 6, and 7 is depicted at the bottom; skipped exon 6 is highlighted in orange. **(C)** Viabilities of control (non-targeting: NT) and RPL22 knock out (KO) MV4;11, MOLM13, and K562 cells treated with a serial dilution range of C16 for 72 hours, relative to viability of DMSO-treated cells ($n = 3$; Mean \pm SEM). **(D)** Western blot analysis of p53 levels in control (NT) and RPL22 knockout (KO) MV4;11 and MOLM13 cells treated with either 0.1% DMSO or C16 (MV4;11, 200 nM; MOLM13, 400 nM) for 72 hours. α -Actinin is loading control. Representative images from three biological replicates shown. Raw unprocessed gel images are presented in **Figure 6—source data 5**. **(E)** Heatmap, showing significant changes in the expression of consensus p53 target genes (Fischer, 2017) between the indicated pairwise comparisons of RNA-Seq datasets. Note that only consensus p53 target genes altered in expression by C16 in control (NT) cells are represented. **(F)** Sashimi plot quantifying read junctions that span exons 5–7 of *MDM4* in RPL22KO MV4;11 cells treated with DMSO or C16. Numbers in the arcs display junction depth. The location of exons 5, 6, and 7 is depicted at the bottom; skipped exon 6 is highlighted in orange. Corresponding NT images are presented alongside RPL22KO images in **Figure 6—figure supplement 3B**. **(G)** Western blots, comparing the effects of 72 hours of DMSO (DM) or C16 treatment (MV4;11, 200 nM; MOLM13, 400 nM) of control (NT) or RPL22 knockout (KO) MV4;11 (left) or MOLM13 (right) cells on levels of MDM4, p21, RPL22L1, RPL22, and GAPDH (loading control). Representative images from three biological replicates are shown. Raw unprocessed gel images are presented in **Figure 6—source data 9**.

Figure 6—figure supplement 1. WINi alter the abundance of alternatively-spliced mRNA isoforms. (A) Western blots comparing the effects of 72 hour DMSO (DM) or C16 treatment of MV4;11 (top) or MOLM13 (bottom) cells on levels of p53 and GAPDH (loading control). Representative images from three biological replicates are shown. Raw unprocessed gel images are presented in **Figure 6—source data 1**. (B) Differential alternative splicing events impacted by C6 (red) or C16 (blue) treatment of MV4;11 cells were quantified by rMATS. The number of significantly different events ($> 5\% \Delta\psi$; FDR < 0.05) for each WIN site inhibitor are depicted in the graph. "RI" is retained intron; "MEX" is mutually exclusive exons; "A3SS" is alternative 3' splice site; "A5SS" is alternative 5' splice site; "SE" is skipped exon. See **Figure 6—source data 2** for output of rMATS analysis. (C) Sashimi plot quantifying read junctions that span exons 12–17 of *KRBA1* in MV4;11 cells treated with DMSO (green) or C16 (blue). Numbers in the arcs display junction depth. Skipped exon 15 is highlighted in orange. (D) As in (C) but for read junctions that span exons 20–22 of *TTF2*. Skipped exon 21 is highlighted in orange. (E) As in (C), but for read junctions that span exons 2 and 3 of *RPL22L1*. The location of exons 2 and 3 is depicted at the bottom. Splicing of exon 2 to the distal acceptor site in exon 3 results in an mRNA encoding RPL22L1a (orange); splicing to the proximal acceptor site in exon 3 results in an mRNA encoding RPL22L1b (yellow). (F) Left: Representation of amplicons used to discriminate between different *MDM4* (top) and *RPL22L1* (bottom) isoforms via semi-quantitative PCR. Right: Results of semi-quantitative PCR analysis for the various isoforms of *MDM4* and *RPL22L1*, and a *GAPDH* control, in MV4;11 or MOLM13 cells treated for 48 hours with DMSO or C16 (MV4;11, 100 nM; MOLM13, 250 nM; $n = 3$). All three biological replicates for DMSO and C16 are shown. Raw unprocessed gel images for the data in (F) are presented in **Figure 6—source data 3**. (G) Left: Representation of amplicons used to discriminate between *MDM4* (top) and *RPL22L1* (bottom) isoforms via RT-qPCR. Right: Results of RT-qPCR analysis for the various isoforms of *MDM4* (top) and *RPL22L1* (bottom) in MV4;11 or MOLM13 cells treated for 48 hours with DMSO or C16 (MV4;11, 100 nM; MOLM13, 250 nM; $n = 3$; Mean \pm SEM). For each amplicon, isoform levels are expressed relative to the DMSO control. P-values are represented by asterisks: $^* \leq 0.05$, $^{***} \leq 0.01$, $^{****} \leq 0.001$.

Figure 6—figure supplement 2. Impact of RPL22 loss on the response of MLLr cells to WINi. (A) Western blot analysis of RPL22 expression in MV4;11, MOLM13, and K562 cells electroporated with Cas9 and either scrambled non-targeting (NT) control or *RPL22*-targeting sgRNAs. GAPDH and α -Actinin are loading controls. Representative images from three biological replicates shown. Raw unprocessed gel images are presented in **Figure 6—source data 4**. (B) GI₅₀ values of C16 in NT and RPL22 KO MV4;11, MOLM13, and K562 cells in a 72 hour assay ($n = 3$; Mean \pm SEM). (C) Number of genes with significantly (FDR < 0.05) altered transcript levels following treatment of RPL22 knock out (KO) or control (NT) cells treated with DMSO or 100 nM C16 for 48 hours, as determined by RNA-Seq ($n = 4$). See **Figure 6—source data 6** for complete output of RNA-Seq analysis. (D) Volcano plots, showing pairwise transcript level alterations in NT (control) and RPL22 KO MV4;11 cells treated 48 hours with DMSO or 100 nM C16 (red indicates FDR < 0.05). The location of transcripts from *ZMAT3* and *RPL22L1* are indicated. (E) Transcript level changes in WDR5-bound (left) and non-bound (right) RPGs in each of the indicated pairwise comparisons of RNA-Seq datasets. (F) Enrichment analysis of genes differentially induced by C16 in RPL22KO cells compared to control (NT) cells. KEGG and Hallmark.MSigDB pathways are shown. Fold enrichment of indicated pathways is presented on the x-

axis, the number of genes is shown in italics in each bar, and colors represent $-\text{Log}_{10}$ FDR. See **Figure 6—source data 7** for complete enrichment analyses. **(G)** As in **(F)** but for suppressed genes. **(H)** Transcript level changes in mitochondrial ribosomal protein genes elicited by C16 in NT or RPL22KO cells.

Figure 6—figure supplement 3. Impact of RPL22 loss on the abundance of alternatively-spliced mRNA isoforms in MV4;11 cells. **(A)** Differential alternative splicing events affected by C16 treatment of control (NT) or RPL22 knockout (KO) MV4;11 cells were quantified by rMATS. The types of alternative splicing events are cartooned at left, and the number of significantly different events ($> 5\% \Delta\psi$; FDR < 0.05) depicted in the graph. See **Figure 6—source data 8** for output of rMATS analysis. **(B)** Sashimi plot quantifying read junctions that span exons 5–7 of *MDM4* in NT or RPL22KO MV4;11 cells treated with DMSO or C16. Numbers in the arcs display junction depth. The location of exons 5, 6, and 7 is depicted at the bottom; skipped exon 6 is highlighted in orange. Note that RPL22KO images are also represented in **Figure 6F**. **(C)** As in **(B)** but for read junctions that span exons 2 and 3 of *RPL22L1*. The location of exons 2 and 3 is depicted at the bottom. Splicing of exon 2 to the distal acceptor site in exon 3 results in an mRNA encoding RPL22L1a (orange); splicing to the proximal acceptor site in exon 3 results in an mRNA encoding RPL22L1b (yellow).

Figure 6—source data 1. Raw unprocessed gel images corresponding to Figure 6—figure supplement 1A.

Figure 6—source data 2. Output of rMATS analysis of MV4;11 cells treated with C6/C16.

Figure 6—source data 3. Raw unprocessed gel images corresponding to Figure 6—figure supplement 1F.

Figure 6—source data 4. Raw unprocessed gel images corresponding to Figure 6—figure supplement 2A.

Figure 6—source data 5. Raw unprocessed gel images corresponding to Figure 6D.

Figure 6—source data 6. Output of RNA-Seq analysis of NT and RPL22KO MV4;11 cells treated with C16.

Figure 6—source data 7. GSEA Hallmark and GOBP enrichment analysis of differentially expressed genes in RNA-Seq of NT and RPL22KO MV4;11 cells treated with C16.

Figure 6—source data 8. Output of rMATS analysis of NT and RPL22KO MV4;11 cells treated with C16.

Figure 6—source data 9. Raw unprocessed gel images corresponding to Figure 6G.

Supplementary File 1—Key Resources Table.

Acknowledgements

For reagents we thank D. Trono and F. Zhang. For assistance we thank Lu Chen, David Cortez, Rachel Green, Matthew Hall, Ian Macara, Kavi Mehta, Bill Moore, Jonathan Shrimp, and Jamie Wangen. The VANTAGE Shared Resource is supported by the CTSA Grant (RR024975), the Vanderbilt Ingram Cancer Center (CA068485), the Vanderbilt Vision Center (EY008126), and NIH/NCRR (RR030956). Core services for QuantiGene assays performed through Vanderbilt University Medical Center's Digestive Disease Research Center were supported by NIH grant DK058404. We acknowledge support of the Vanderbilt Proteomics Core in the Mass Spectrometry Research Center, supported in part by the Vanderbilt Ingram Cancer Center. This work was supported by awards from the NIH/NCI—under Chemical Biology Consortium Contract No. HHSN261200800001E (SWF and WPT), and CA200709 (WPT)—as well as grants from the Robert J. Kleberg, Jr., and Helen C. Kleberg Foundation (WPT and SWF). BCG was supported by the Brock Family Fellowship, the NCI (CA217834/CA268703), and an American Society for Clinical Oncology Young Investigator's Award.

Author Contributions

Conceptualization, GCH and WPT; Methodology, GCH, KLR, and ACF; Software, GCH, JW, KLR, TT, and QL; Formal Analysis, GCH, JW, KLR, TT, and QL; Investigation, GCH, KLR, PP, ACF, SLL, BCG, EMR, BNS, MJS, and SG; Data Curation, GCH, JW, KLR, TT, and QL; Writing–Original Draft, GCH and WPT; Writing–Review & Editing, GCH, JW, KLR, PP, TT, ACF, SLL, BCG, BNS, MRS, MJS, SG, TL, SWF, QL, and WPT; Visualization, GCH, JW, and TL; Supervision, WPT; Funding Acquisition, SWF and WPT.

Declarations of Interest

Fesik, S. W., Stauffer, S. R., Salovich, J. M., Tansey, W. P., Wang, F., Phan, J., Olejniczak, E. T., inventors. WDR5 inhibitors and modulators. United States Patent US 10,501,466. 10 December 2019.

Fesik, S. W., Stauffer, S. R., Tansey, W. P., Olejniczak, E. T., Phan, J., Wang, F., Jeon, K., Gogliotti, R. D., inventors. WDR5 inhibitors and modulators. United States Patent US 10,160,763. 25 December 2018.

Materials and Methods

Key resources

All key resources are provided in **Supplementary File 1—Key Resources Table**.

Materials availability

Plasmids and cell lines generated in this study are available upon request from the corresponding author (william.p.tansey@vanderbilt.edu).

Data availability

Ribo-Seq, RNA-Seq, and CRISPR screen data are deposited at Gene Expression Omnibus (GEO) with the accession number GSE206931. Quantitative proteomics data are deposited at the ProteomeXchange Consortium via the PRIDE partner repository with identifier PXD035129.

Cell lines

MV4;11 (RRID: CVCL_0064), MOLM13 (RRID: CVCL_2119), and K562 (RRID: CVCL_0004) cell lines and their derivatives were cultured in RPMI-1640 media with 10% FBS, 10 U/mL penicillin, and 10 µg/mL streptomycin at 37°C and 5% CO₂. HEK293T (RRID: CVCL_1926) cells were cultured in DMEM media with 10% FBS, 10 U/mL penicillin, and 10 µg/mL streptomycin at 37°C and 5% CO₂. MV4;11 and MOLM13 cell lines are male. K562 and HEK293T cell lines are female. Cell lines were split every 2 to 4 days and suspension cells maintained between 1x10⁵ and 1x10⁶ cells/mL. All cell lines tested negative for mycoplasma.

Generation of *RPL22*-null cell lines

MV4;11, MOLM13, and K562 control (NT) and *RPL22* knockout (KO) cell lines were generated by CRISPR using the multi-guide Synthego Gene Knockout System. Briefly, ribonucleoprotein (RNP) complexes containing Cas9-2NLS (Synthego) and either non-targeting (NT) control sgRNA#1 (Synthego) or *RPL22* sgRNAs (Synthego Gene Knockout Kit v2 – human – *RPL22*) were formed by incubating 90 pmol sgRNA and 10 pmol Cas9-2NLS in Buffer R (Component of Neon Transfection System Kit; Thermo Scientific) at room temperature for 10 minutes. MV4;11, MOLM13, or K562 cells were electroporated (2 x 10⁵ cells per reaction) with RNP complexes using the Neon Transfection System (Thermo Fisher Scientific) with the following parameters using Buffer R in 10 µL reactions: MV4;11 cells: 1175 V Pulse, 40 ms Pulse Width, 1 Pulse; MOLM13 cells: 1075 V Pulse, 30 ms Pulse Width, 2 Pulses; K562 cells: 1450 V Pulse, 10 ms Pulse Width, 3 Pulses. Cells recovered undisturbed in media absent of antibiotics for 48 hours before expansion and screening for loss of *RPL22* expression by western blot analysis.

Multiplex gene expression assays

Cells were treated with 0.1% DMSO or varying concentrations of C6 or C16 for 24 hours. A custom QuantiGene Plex panel (ThermoFisher Scientific) was used in conjunction with the QuantiGene Sample Processing Kit for cultured cells (ThermoFisher Scientific), and QuantiGene Plex Assay kit (ThermoFisher Scientific) to quantify transcripts following the manufacturer's instructions. Probe regions and accession numbers are as follows: *RPS24* (NM_001026, region 5-334), *RPL35* (NM_007209, region 2-430), *RPL26* (NM_000987, region 37-445), *RPS14* (NM_005617, region 61-552), *RPL32* (NM_000994, region 95-677), *RPS11* (NM_001015, region 139-634), *RPL14* (NM_003973, region 108-530), and *GAPDH* (NM_002046, region 2-407). The Average Net Mean Fluorescence Intensity was read on a Luminex FLEXMAP 3D System (Invitrogen). Signals from RPGs were normalized internally to those from *GAPDH*, and then to the DMSO control. Dose response curves from the mean of biological replicates were calculated with the R package *drc* (Ritz et al, 2015).

Western blot analysis

Cells were collected by centrifugation and washed once with ice-cold PBS. Cells were lysed in either RIPA buffer (50 mM Tris, pH 8.0; 150 mM NaCl; 5 mM EDTA; 1.0% NP-40; 0.5% Sodium Deoxycholate; 0.1% SDS) or Triton-X buffer (50 mM Tris, pH 8.0; 150 mM NaCl; 5 mM EDTA; 1% Triton X-100), each supplemented with protease and phosphatase inhibitors (2X cOmplete, EDTA-free, Protease Inhibitor Cocktail [Roche]; 1X PhosSTOP Phosphatase Inhibitor [Roche]; 100 µg/mL Pefabloc SC [Roche]),

while incubating on ice for 10 minutes. Chromatin was sheared by brief sonication at 25% on ice, insoluble material cleared by centrifugation, and protein quantified by Pierce BCA Protein Assay (Thermo Scientific). Protein samples were diluted to equal concentrations in lysis buffer and boiled for 5 minutes in 1X Laemmli Sample Buffer. Samples were run on 4-20% TGX Precast Polyacrylamide Gels (Bio-Rad) or hand-cast single percentage polyacrylamide gels, wet transferred to Amersham Protran Western Blotting Nitrocellulose Membrane (Cytiva) for one hour at 100V in Towbin Buffer (25 mM Tris; 192 mM glycine; 10% methanol), and blocked in 5% milk in TBS-T before incubation overnight with one of the following primary antibodies: anti-p53 (Santa Cruz Biotechnology, Cat# sc-126), anti-RPL22 (Santa Cruz Biotechnology, Cat# sc136413), anti-RPL22L1 (Thermo Fisher Scientific, Cat# PA5-63266), anti-MDM4 (Sigma-Aldrich, Cat# M0445), anti-p21 (Cell Signaling Technology, Cat# 2947), anti-H2A.X (Cell Signaling Technology, Cat# 2595), anti-phospho-H2A.X (S139) (Cell Signaling Technology, Cat# 9718), anti- α -actinin (Cell Signaling Technology, Cat# 12413), or anti-GAPDH (Cell Signaling Technology, Cat# 8884). Membranes were washed three times with TBS-T and, if required, incubated with anti-Mouse-HRP secondary antibody (Jackson ImmunoResearch Laboratories, Inc., Cat# 115-035-174) or anti-Rabbit-HRP (Cell Signaling Technology, Cat# 7074) for one hour. Blots were developed with Clarity ECL Western Blotting Substrate (Bio-Rad) and imaged on a ChemiDoc Imaging System (Bio-Rad).

Ribo-Seq

Ribo-seq was performed as previously described with some modifications (McGlinchy & Ingolia, 2017). MV4;11 cells treated for 48 hours with either 0.1% DMSO, 2 μ M C6, or 100 nM C16 were washed with ice-cold PBS and lysed in 400 μ L Lysis Buffer (20 mM Tris, pH 7.4; 150 mM NaCl; 15 mM MgCl₂; 1 mM DTT; 100 μ g/mL cycloheximide; 1% Triton X-100; 25 U/mL Turbo DNase I) by incubation on ice for 10 minutes followed by homogenization by syringe. Lysates were cleared by centrifugation at 4°C, and RNA quantified by Qubit RNA HS Assay (Invitrogen) following manufacturer's instructions. 30 μ g RNA was diluted in 200 μ L Polysome Buffer (20 mM Tris, pH 7.4; 150 mM NaCl; 5 mM MgCl₂; 1 mM DTT; 100 μ g/mL cycloheximide) and incubated with 15 U RNase I (Lucigen) for 45 minutes while rotating at room temperature. RNA digestion was quenched with 10 μ L SUPERaseIn RNase Inhibitor (Invitrogen) and samples transferred to 13 mm x 51 mm ultracentrifuge tubes (Beckman-Coulter), underlaid with 900 μ L 1 M sucrose in polysome buffer supplemented with 20 U/mL SUPERaseIn RNase Inhibitor, and centrifuged at 540,628 x *g* one hour at 4°C. Ribosome pellets were suspended in TRIzol Reagent (Invitrogen), and RNA extracted from ribosome pellets by Direct-zol RNA MiniPrep Kit (Zymo Research). RNA and carrier glycogen were precipitated by adding 1.5 volumes 100% isopropanol supplemented with 0.12 M NaOAc, pH 5.5, followed by incubation on dry ice for 30 minutes and centrifugation at 16,800 x *g* for 30 minutes at 4°C. RNA was resuspended in 5 μ L 10 mM Tris, pH 8.0, and 1X Denaturing Sample Loading Buffer (98% Formamide; 10 mM EDTA; 300 μ g/mL bromophenol blue) and subjected to electrophoresis on 15% polyacrylamide TBE-Urea gels (Invitrogen). Gels were stained briefly with 1X SYBR Gold (Invitrogen), 17-34 nucleotide fragments excised, and RNA fragments extracted by mechanical disruption, suspension in 500 μ L RNA Gel Extraction Buffer (300 mM NaOAc, pH 5.5; 1 mM EDTA; 0.25% SDS), freezing on dry ice for 30 minutes, and rotating overnight at room temperature. Polyacrylamide was removed by centrifugation through Costar Spin-X columns (Corning) and RNA precipitated with isopropanol as described above. RNA was dephosphorylated by incubation with 5 U T4 Polynucleotide Kinase in 1X T4 PNK Buffer (New England BioLabs) supplemented with SUPERaseIn RNase Inhibitor for one hour at 37°C and ligated to bar-coded linkers (NI-810: /5Phos/NNNNNATCGTAGATCGGAAGAGCACACGTCTGAA/3ddC/; NI-811: /5Phos/NNNNNAGCTAAGATCGGAAGAGCACACGTCTGAA/3ddC/; NI-812: /5Phos/NNNNNCGTAAAGATCGGAAGAGCACACGTCTGAA/3ddC/) pre-adenylated with 100 U of T4 RNA Ligase 2, truncated K227Q, in 1X T4 RNA Ligase Buffer (New England BioLabs) supplemented with 35% w/v PEG-8000 and incubated at 37°C for three hours. Ligation was verified by electrophoresis, samples combined, and linker-ligated RNA precipitated with isopropanol as described above. Ribosomal RNA was depleted from samples using the RiboCop rRNA Depletion Kit (Lexogen) and RNA precipitated with isopropanol as described above. Linker-ligated RNA was reverse transcribed with 200 U SuperScript III in 1X First Strand Buffer (Invitrogen), dNTPs, DTT, 10 U SUPERaseIn RNase Inhibitor and primer NI-802 (/5Phos/NNAGATCGGAAGAGCGTCGTGTAGGGAAAGAG/iSp18/GTGACTGGAGTTCAGACGTGTGCTC). RNA template was hydrolyzed for 15 minutes at 98°C in the presence of 0.1M NaOH and cDNA precipitated with isopropanol as described previously. Reverse-

transcribed DNA was subjected to electrophoresis on 15% polyacrylamide Novex TBE-Urea gels (Invitrogen) and the 105-nucleotide reverse-transcription product excised from polyacrylamide as described above, except with DNA Gel Extraction Buffer (300 mM NaCl; 10 mM Tris, pH 8.0; 1 mM EDTA). cDNA was circularized with 100 U CircLigase ssDNA Ligase (Lucigen) in the presence of 1X CircLigase Buffer, ATP, and MnCl₂ at 60°C for one hour followed by 80°C for 10 minutes. Circularized cDNA was quantified by qPCR, amplified using Phusion Polymerase (New England BioLabs) with unique dual-indexed primers (UDI0050_i5: AATGATACGGCGACCACCGAGATC-TACACGCTCCGACACACTCTTTCCCTACACGACGCT CTTCCGATCT; UDI0050_i7: CAAGCAGAAGACGGCATAACGAGATTAGAGC-GCGTGACTGGAGTTCAGACGTGT; UDI0051_i5: AATGATACGGCGACCACCGAGAT-CTACACATAACCAAGACACTCTTTCCCTACACGACGCT; UDI0051_i7: CAAGCAGAAGACGGCATAACGAGATAACCTGTTGTGACTGGAGTTCAGACGTGT; UDI0052_i5: AATGATACGGCGACCACCGAGATCTACACGCGTTGGAACACTCTTTCCCTACACGACGCT; UDI0052_i7: CAAGCAGAAGACGGCATAACGAGATGGTTCCACCGTG-ACTGGAGTTCAGACGTGT), amplicons subjected to electrophoresis on 8% polyacrylamide Novex gels (Invitrogen), and products >160 bp excised as described. Libraries were submitted to VANTAGE (Vanderbilt Technologies for Advanced Genomics) for sequencing on a NovaSeq 6000.

Ribo-Seq data analysis

Adapters were trimmed from reads using *cutadapt* (Martin, 2011), and UMIs removed from reads and attached to read IDs using *UMI-tools* (Smith et al, 2017). Reads were demultiplexed using *sabre* and aligned against ribosomal RNA using *bowtie2* (Langmead & Salzberg, 2012). Reads not mapping to rRNA were mapped to the hg19 transcriptome using *STAR* (Dobin et al, 2013) and deduplicated using *UMI-tools* (Smith et al., 2017). Count tables for reads mapping to central ORFs were generated using the coverage command from *bedtools* (Quinlan & Hall, 2010). After batch removal, Ribo-Seq read counts were normalized to mRNA read counts using *Xtail* (Xiao et al, 2016) to calculate translation efficiencies and statistics. FDR values were calculated using the Cochran-Mantel-Haenszel test (CMH). Genes with significantly altered translation efficiencies were those with FDR < 0.05 and absolute log₂FC > 0.25. Identification of optimal ribosome protected fragment (RPF) P-site offsets, RPF triplet periodicity, and RPF localization to CDS and UTR regions was performed with the R package *riboWaltz* (Lauria et al, 2018).

RNA-Seq

For RNA-Seq performed in parallel with Ribo-Seq, RNA was isolated by Direct-zol RNA MiniPrep Kit (Zymo Research) from 100 μ L of cell lysates after homogenization by syringe and clearing by centrifugation. For combination WINi/BETi treatment, MV4;11 cells were treated for 48 hours with either 0.2% DMSO, 100 nM C16, 2.5 nM mivebresib, or combined 100 nM C16 and 2.5 nM mivebresib, and RNA isolated by Direct-zol RNA MiniPrep Kit (Zymo Research) with on-column DNase-treatment. For RNA-Seq in MV4;11 NT and RPL22 KO cells, cultures were treated for 48 hours with either 0.1% DMSO or 100 nM C16 before RNA isolation as described above for WINi/BETi RNA-Seq. For all RNA-Seq experiments, RNA was submitted to the Vanderbilt Technologies for Advanced Genomics (VANTAGE) core facility for library preparation with rRNA-depletion using standard Illumina protocols and sequencing on an Illumina NovaSeq 6000.

RNA-Seq data analysis

Adapters were trimmed from RNA-Seq reads using *cutadapt* (Martin, 2011) and reads aligned to the hg19 genome using *STAR* (Dobin et al., 2013). Gene expression was quantified using *featureCounts* (Liao et al, 2014) and differential analysis performed using *DESeq2* (Love et al, 2014) which calculates *p*-values through the Wald test and adjusts *p*-values by the Benjamini-Hochberg procedure to calculate FDR. Changes in levels of alternative splicing events were quantified using *rMATS* which calculates changes in exon inclusion levels ($\Delta\psi$), and *p*-values through a likelihood-ratio test. Genes with significantly altered transcript levels are those with FDR < 0.05. Significant changes in alternative splicing events are those with FDR < 0.05 and $\Delta\psi$ > 5%.

Generation of Cas9-expressing MV4;11 cells

To generate Cas9 expression lentivirus, HEK293T cells were transfected with the viral transfer plasmid lentiCas9-Blast (Sanjana et al, 2014) (gift from Feng Zhang; Addgene plasmid # 52962), the viral

packaging plasmid psPAX2 (gift from Didier Trono; Addgene plasmid # 12260), and the viral envelope plasmid pMD2.G (gift from Didier Trono; Addgene plasmid # 12259) using Lipofectamine 3000 Transfection Reagent (Invitrogen). After 48 hours, virus-containing media was collected and used to transduce MV4;11 cells by spinfection (2 hours; 1000 x g; room temperature; 8 µg/mL hexadimethrine bromide). Following spinfection, virus-containing media was replaced with fresh media and cells allowed to recover for 48 hours before selection with 10 µg/mL blasticidin (Research Products International). A clonal MV4;11 Cas9 cell line was established by serial dilution of the population and screening for retention of WIN site inhibitor sensitivity.

Tier 1 CRISPR screen

Tier 1 CRISPR screens were performed essentially as described (Joung et al., 2017). Briefly, the Human GeCKOv2 CRISPR Knockout Pooled Library (A+B) in the lentiGuide-Puro vector backbone (gift from Feng Zhang; Addgene Plasmid # 1000000048) was amplified and purified as directed by Addgene. Lentiviral particles were generated by transfecting HEK293T cells with the GeCKOv2 CRISPR Knockout Pooled Plasmid Library, psPAX2 (gift from Didier Trono; Addgene plasmid # 12260), and pMD2.G (gift from Didier Trono; Addgene plasmid # 12259) using Lipofectamine 3000 Transfection Reagent (Invitrogen). After 48 hours, viral media was collected, aliquoted, and stored at -80°C. In duplicate, clonal Cas9-expressing MV4;11 cells were transduced by spinfection (2 hours; 1000 x g; room temperature; 8 µg/mL hexadimethrine bromide) with a volume of virus-containing media sufficient to infect 30 percent of cells and at a scale to generate >200 transduced cells per sgRNA in the library. Cells recovered in fresh media overnight, were split 1:2, and selected with 1 µg/mL puromycin for 48 hours to generate the MV4;11 Cas9 + GeCKOv2 population.

MV4;11 Cas9 and MV4;11 Cas9 + GeCKOv2 cells were treated with either 0.1% DMSO or 2 µM C6, replenished every three days with fresh media and C6, and counted daily by trypan blue exclusion. DMSO-treated populations were grown until cultures reached > 8 x 10⁵ cells/mL to verify C6-treatment efficacy. C6-treated MV4;11 Cas9 + GeCKOv2 populations were maintained below 8 x 10⁵ cells/mL and grown until a resistant population emerged relative to C6-treated MV4;11 Cas9 cells. Genomic DNA was isolated from MV4;11 Cas9 + GeCKOv2 cells collected before and following sustained C6-treatment using the Quick-gDNA MidiPrep Kit (Zymo Research) per manufacturer's directions. Sequencing libraries were generated by amplifying sgRNA sequences from genomic DNA using bar-coded Illumina-compatible adapter-containing primers and NEBNext High-Fidelity 2x PCR Master Mix (New England BioLabs). PCR products were pooled and purified with a ZymoSpin V column with Reservoir (Zymo Research). Libraries were sequenced on an Illumina NextSeq 500 in the Vanderbilt Technologies for Advanced Genomics (VANTAGE) core facility.

Cloning targeted sgRNA library for second tier screen

The Tier 2 sgRNA plasmid library was generated as previously described with some modifications (Joung et al., 2017). Briefly, sgRNA sequences against a curated collection of genes and 200 non-targeting control sgRNA sequences were extracted from the Brunello sgRNA Library (Doench et al., 2016). For genes of interest not included in the Brunello library, four sgRNAs targeting each gene were designed with the CHOPCHOP sgRNA design tool (Labun et al., 2019). sgRNA sequences were appended with 5' and 3' flanking sequences and synthesized as an Oligo Pool (**Figure 4 — source data 2**; Twist Bioscience) followed by PCR amplification using NEBNext HiFidelity 2X Master Mix (New England BioLabs) with Fwd Primer (GTAACCTTGAAAGTATTTTCGATTTCTTG-GCTTTATATATCTTGTGGAAAGGACGAAACACC) and KO Rev Primer (ACTTTTTCAAGTTGATAAC-GGACTAGCCTTATTTAACTTGCTATTTCTAGCTCTAAAAC). PCR amplicons were subjected to agarose gel size selection using the NucleoSpin Gel and PCR Clean-up Kit (Macherey-Nagel). Amplicons were cloned into BsmBlv2-digested (New England BioLabs) lentiGuide-PURO plasmid (gift from Feng Zhang; Addgene plasmid # 52963) via Gibson Assembly (New England BioLabs). Gibson Assembly products were precipitated with isopropanol and electroporated into Endura ElectroCompetent *E. coli* (Lexogen). Amplified plasmids were isolated from *E. coli* using the Nucleobond Xtra Maxi EF Kit (Macherey-Nagel) and adequate representation of sgRNAs in the library was verified by next-generation sequencing and analysis with the python script *count_spacers.py* (Joung et al., 2017).

Tier 2 CRISPR screen

Tier 2 sgRNA Library lentiviral particles were generated and MV4;11 Cas9 cells transduced as described above for the Tier 1 screen at a scale to achieve >500 cells per sgRNA in the library. MV4;11 Cas9 + Targeted sgRNA Library populations were treated with either 0.1% DMSO, 2 μ M C6, or 100 nM C16 for 15 days. Cultures were maintained below 8×10^5 cells/mL and cultures replenished every three days with media and fresh DMSO, C6, or C16. Genomic DNA was isolated, and Illumina-compatible next-generation sequencing libraries generated as described above for the Tier 1 screen. Libraries were sequenced on an Illumina NovaSeq 6000 in the Vanderbilt Technologies for Advanced Genomics (VANTAGE) core facility.

CRISPR Screen data analysis

Adapters were trimmed from reads using *cutadapt* (Martin, 2011). Generation of sgRNA count tables and determination of significant gene-level alterations in sgRNA representation were performed using *MAGeCK* (Li et al, 2014) which utilizes a negative binomial model to determine *p*-values of sgRNA changes and ranks sgRNAs by significance. Gene-level alterations and *p*-values were calculated from the ranked list of sgRNAs using the modified robust ranking aggregation (α -RRA) algorithm and FDR values calculated by the Benjamini-Hochberg procedure. Tier 1 screen analysis compared populations before and after C6 treatment. Tier 2 screen analysis compared DMSO-treated populations to C6- or C16-treated populations. Significantly enriched or depleted genes were those with FDR < 0.05.

Cell viability assays

Opaque 384-well plates were seeded with 250 cells per well in 25 μ L media supplemented with either 0.1% DMSO or a 3-fold dilution series of C6 or C16, all in technical quadruplicate wells. Cells were grown for 72 hours before equilibrating to room temperature and addition of 12.5 μ L CellTiter-Glo Luminescent Cell Viability Assay reagent (Promega). At room temperature and protected from light, plates were rocked for 5 minutes, incubated for 20 minutes, and luminescence measured on a GloMax Explorer Multimode Microplate Reader (Promega). To calculate relative cell viability, mean fluorescence from quadruplicate treatment wells was divided by mean fluorescence from quadruplicate DMSO wells. Dose response curves, GI₅₀ concentrations, and standard error values were calculated from at least three biological replicates with the R package *drc* (Ritz et al., 2015).

Synergy assays

Opaque 384-well plates were seeded with 250 cells per well in 25 μ L media supplemented with either 0.2% DMSO, a three-fold dilution series of either C16 or Compound 2, or a combination of three-fold dilutions of both C16 and Compound 2 covering a 7x7 dose matrix, all in quadruplicate wells. Compound 2 consisted of either nutlin-3a (Cayman Chemical Company), rapamycin (MedChem Express), pinometostat (Cayman Chemical Company), harmine (Sigma-Aldrich), mivebresib (Cayman Chemical Company), venetoclax (Cayman Chemical Company), etoposide (Cayman Chemical Company), olaparib (Cayman Chemical Company), VE-821 (Cayman Chemical Company), pemrametostat (Selleck Chemicals), or alvespimycin (Cayman Chemical Company). Following 72 hours, plates were equilibrated to room-temperature and 12.5 μ L CellTiter-Glo Cell Viability Assay (Promega) reagent added to each well. While protected from light, plates were rocked for five minutes, incubated for 20 minutes, and luminescence measured on a GloMax Explorer Multimode Microplate Reader (Promega).

Synergy assay data analysis

Technical replicate wells were averaged and resulting means used to calculate relative cell viability by dividing drug treatment by DMSO treatment. Mean δ -scores and standard deviations were calculated from three biological replicates via *SynergyFinder Plus* (Zheng et al, 2022) using the Zero Interaction Potency (ZIP) model (Yadav et al., 2015). ZIP δ -scores represent the percent of growth inhibition beyond that expected if the agents do not potentiate one another. δ -scores greater than zero are synergistic, δ -scores of zero are additive, and δ -scores less than zero are antagonistic. Statistical significances of peak synergistic and antagonistic δ -scores were calculated by one-sample t-tests using the *tsum.test* function from the R package *PASWR*. Significant synergy and antagonism δ -scores were those with *p* < 0.05.

Quantitative proteomics

In quadruplicate, MV4;11 cells were treated with 0.1% DMSO or 250 nM C16 for either 24 or 72 hours. Cells were collected by centrifugation and washed three times with ice-cold 1X PBS before lysis on ice in SDS Lysis Buffer (5% SDS; 50 mM Ammonium Bicarbonate). Chromatin was sheared by brief sonication at 25% on ice and insoluble material cleared by centrifugation. Soluble proteins were quantified by Pierce BCA Protein Assay (Thermo Scientific).

Protein samples for LC-MS/MS analyses were prepared by S-Trap (ProtiFi) digestion. Protein samples (50 µg) were reduced with DTT (Millipore Sigma) at a final concentration of 20 mM at 95°C for 10 minutes and alkylated with iodoacetamide (Millipore Sigma) at a final concentration of 40 mM at RT for 30 minutes in the dark. Aqueous phosphoric acid (Fisher Scientific) was added to the samples at a final concentration of 1.2% followed by 90% methanol containing 100 mM TEAB at 6.6 times the volume of the sample. The samples were loaded on the S-Trap micro columns and centrifuged at 4000 x *g* until all the volume was passed through the column. The columns were washed four times with 150 µL 90% methanol containing 100 mM TEAB, pH 7.1. Proteins were digested with trypsin gold (Promega) at 1:50 enzyme to protein ratio in 50 mM TEAB, pH 8.0, for one hour at 47°C. Peptides were eluted by serial addition of 40 µL each of 50 mM TEAB, 0.2% formic acid, and 35 µL of 0.2% formic acid in 50% acetonitrile. Eluted peptides were dried in a speed-vac concentrator, resuspended in aqueous 0.1% formic acid, and analyzed by LC-coupled tandem mass spectrometry (LC-MS/MS).

An analytical column (360 µm O.D. x 100 µm I.D.) was packed with 25 cm of C18 reverse phase material (Jupiter, 3 µm beads, 300Å; Phenomenex) directly into a laser-pulled emitter tip. Peptides were loaded on the reverse phase column using a Dionex Ultimate 3000 nanoLC and autosampler. The mobile phase solvents consisted of 0.1% formic acid, 99.9% water (solvent A) and 0.1% formic acid, 99.9% acetonitrile (solvent B). Peptides were gradient-eluted at a flow rate of 350 nL/min, using a 120-minute gradient. The gradient consisted of the following: 1-100 min, 2-38% B; 100-108 min, 38-90% B; 108-110 min, 90% B; 110-111 min, 90-2% B; 111-120 min (column re-equilibration), 2% B. Upon gradient elution, peptides were analyzed using a data-dependent method on an Orbitrap Exploris 480 mass spectrometer (Thermo Scientific), equipped with a nanoelectrospray ionization source. The instrument method consisted of MS1 using an MS AGC target value of 3×10^6 , followed by up to 15 MS/MS scans of the most abundant ions detected in the preceding MS scan. The intensity threshold for triggering data-dependent scans was set to 1×10^4 , the MS2 AGC target was set to 1×10^5 , dynamic exclusion was set to 20s, and HCD collision energy was set to 30 nce.

Quantitative proteomics data analysis

For identification of peptides, LC-MS/MS data were searched with *Maxquant*, version 2.0.1.0 (Cox & Mann, 2008). MS/MS spectra were searched with the *Andromeda* search engine (Cox et al, 2011) against a human database created from the UniprotKB protein database (2021) and the default *Maxquant* contaminants. Default parameters were used for *Maxquant*, with the addition of selecting LFQ and match between runs as a global parameter. *Maxquant* parameters included first and main search mass tolerances of 20 ppm and 4.5 ppm, respectively. Variable modifications included methionine oxidation and N-terminal acetylation, and carbamidomethyl cysteine was selected as a fixed modification. A maximum of two missed cleavages was allowed. The false discovery rate (FDR) was set to 0.01 for peptide and protein identifications. Label-free quantitative (LFQ) analysis of identified proteins was performed with the *MSstats* R package (Choi et al, 2014), version 4.0.1, using default parameters which include the following: equalize medians for the normalization method, log2 transformation, Tukey's median polish as the summary method, and model-based imputation. Protein fold changes were considered as significant with adjusted *p*-values ≤ 0.05 .

RNA Isolation and cDNA synthesis

Cell pellets were suspended in TRIzol Reagent (Invitrogen), rotated for 15 minutes at room temperature, and insoluble cellular debris pelleted by centrifugation. The soluble fraction was mixed with equal volume of 100% ethanol and RNA was isolated using the Direct-zol RNA Miniprep Kit (Zymo Research) according to manufacturer's instructions, including on-column DNA digestion. Complementary DNA (cDNA) was synthesized in 20 µL cDNA reactions containing 1 µg RNA, Random Hexamers (Invitrogen), and SuperScript III Reverse Transcriptase (Invitrogen) per manufacturer's

instructions. Final cDNA products were diluted 5-fold with nuclease-free water before use in semi-quantitative RT-PCR or quantitative RT-PCR.

Semi-Quantitative RT-PCR

PCR reactions were performed with 2 μ L cDNA template using primers amplifying splicing variants of *RPL22L1* (*RPL22L1_RTPCR_F*: ATGGCGCCGCAGAAAGAC; *RPL22L1_RTPCR_R*: CTAGTCCTCCGACTCTGATT) or *MDM4* (*MDM4_RTPCR_F*: GAAAGACCCAAGCCCTCTCT; *MDM4_RT_PCR_F*: GCAGTGTGGGGATATCGTCT), or within *GAPDH* (*GAPDH_RTPCR_F*: TCACCAGGGCTGCTTTTAAC; *GAPDH_RTPCR_R*: ATCGCCCCACTTGATTTTGG) using Taq DNA Polymerase (New England BioLabs) with primer-specific annealing temperatures and cycle numbers (*RPL22L1*: 50°C, 30 cycles; *MDM4*: 54°C, 33 cycles; *GAPDH*: 52°C, 27 cycles). PCR Products were electrophoretically separated on 2% agarose gels in TBE buffer, gels incubated 30 minutes in TBE buffer containing 1X SYBR Safe DNA Stain (Invitrogen) with agitation, and imaged on a ChemiDoc Imaging System (Bio-Rad).

Quantitative RT-PCR

qPCR reactions containing 1X KAPA SYBR Fast qPCR Master Mix (Roche), transcript-specific primers, and 2 μ L cDNA template were performed in technical duplicate wells on a C1000 Touch Thermal Cycler (Bio-Rad) with a CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Primer pairs targeted total *RPL22L1* (*RPL22L1ab_qPCR_F*: TCGAGTGGTTGCATCTGACA; *RPL22L1ab_qPCR_R*: TCCTCCGACTCTGATTCATCT), *RPL22L1a* (*RPL22L1a_qPCR_F*: CGCCGCAGAAAGACAGGAA; *RPL22L1a_qPCR_R*: CTCCCGTAGAAATTGCTCAAAT), *RPL22L1b* (*RPL22L1b_qPCR_F*: CGCAGAAAGACAGGAAGCC; *RPL22L1b_qPCR_R*: TGCAAACTAGGGAAGAGAACC), *MDM4* exon 5-6 junction (*MDM4_Jnct_5_6_qPCR_F*: AGAATCTTGTCACCTTTAGCCACT; *MDM4_Jnct_5_6_qPCR_R*: CGAGAGTCTGAGCAGCATCT), *MDM4* exon 6-7 junction (*MDM4_Jnct_6_7_qPCR_F*: TCAAGACCAACTGAAGCAAAGT; *MDM4_Jnct_6_7_qPCR_R*: TAGGCAGTGTGGGGATATCG), *MDM4* exon 4 (*MDM4_Ex_4_qPCR_F*: AGCAACTTTATGATCAGCAGGAG; *MDM4_Ex_4_qPCR_R*: GACGTCCCAGTAGTTCTCC), *MDM4* exon 7 (*MDM4_Ex_7_qPCR_F*: AGAGGAAAGTTCCACTTCCAGA; *MDM4_Ex_7_qPCR_R*: ATGCTCTGAGGTAGGCAGTG), or *GAPDH* (*GAPDH_qPCR_F*: AAGGTGAAGGTCGGAGTCAAC; *GAPDH_qPCR_R*: GTTGAGGTCAATGAAGGGGTC). Ct values for each well were determined by the BioRad CFX Manager Software v3.1 using the regression model, and mean Ct values from technical replicate wells used for subsequent calculations. Relative isoform levels were calculated via the $2^{(-\Delta\Delta Ct)}$ algorithm by internally normalizing isoform-specific Ct values to *GAPDH* Ct values, then relative to DMSO-treatment.

Quantification and statistical analysis

The n for each experiment, representing biological replicates, can be found in the figure legends. The statistical test and threshold for statistical significance for each experiment can be found below.

Structure alignment

Images of C6 and C16 bound to the WIN-Site of WDR5 and overlaid structures in WDR5-binding conformations were generated with *PyMOL* using published X-ray crystal structures [C6, PDB: 6E23 (Aho et al., 2019a); C16, PDB: 6UCS (Tian et al., 2020)].

GSEA and ORA

Gene set enrichment analyses and over-representation analyses were performed with the R package *fgsea* (Korotkevich et al, 2021) using the Molecular Signatures Database v7.4 (Liberzon et al., 2015; Liberzon et al, 2011; Subramanian et al, 2005). Significantly enriched or depleted gene sets were those with FDR < 0.05.

References

- Advani VM, Ivanov P (2019) Translational Control under Stress: Reshaping the Translatome. *BioEssays : News and reviews in molecular, cellular and developmental biology* 41: e1900009
- Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M (2021) MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. *J Hematol Oncol* 14: 121
- Aho ER, Wang J, Gogliotti RD, Howard GC, Phan J, Acharya P, Macdonald JD, Cheng K, Lorey SL, Lu B et al (2019a) Displacement of WDR5 from chromatin by a WIN site inhibitor with picomolar affinity. *Cell Reports* 26:2916-2928
- Aho ER, Weissmiller AM, Fesik SW, Tansey WP (2019b) Targeting WDR5: A WINning Anti-Cancer Strategy? *Epigenet Insights* 12: 2516865719865282
- Ali A, Veeranki SN, Chinchole A, Tyagi S (2017) MLL/WDR5 Complex Regulates Kif2A Localization to Ensure Chromosome Congression and Proper Spindle Assembly during Mitosis. *Dev Cell* 41: 605-622 e607
- Alicea-Velazquez NL, Shinsky SA, Loh DM, Lee JH, Skalnik DG, Cosgrove MS (2016) Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes. *J Biol Chem* 291: 22357-22372
- Bernt KM, Armstrong SA (2011) Targeting epigenetic programs in MLL-rearranged leukemias. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program 2011*: 354-360
- Bieging-Rolett KT, Kaiser AM, Morgens DW, Boutelle AM, Seoane JA, Van Nostrand EL, Zhu C, Houlihan SL, Mello SS, Yee BA et al (2020) Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. *Mol Cell* 80: 452-469 e459
- Blackford AN, Jackson SP (2017) ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. *Mol Cell* 66: 801-817
- Boglev Y, Badrock AP, Trotter AJ, Du Q, Richardson EJ, Parslow AC, Markmiller SJ, Hall NE, de Jong-Curtain TA, Ng AY et al (2013) Autophagy induction is a Tor- and Tp53-independent cell survival response in a zebrafish model of disrupted ribosome biogenesis. *PLoS Genet* 9: e1003279
- Bolshan Y, Getlik M, Kuznetsova E, Wasney GA, Hajian T, Poda G, Nguyen KT, Wu H, Dombrovski L, Dong A et al (2013) Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction. *ACS Medicinal Chemistry Letters* 4: 353-357
- Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT (2017) A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. *Nature Medicine* 23: 461-471
- Bryan AF, Wang J, Howard GC, Guarnaccia AD, Woodley CM, Aho ER, Rellinger EJ, Matlock BK, Flaherty DK, Lorey SL et al (2020) WDR5 is a conserved regulator of protein synthesis gene expression. *Nucleic Acids Res* 48: 2924-2941
- Cai WL, Chen JF, Chen H, Wingrove E, Kurley SJ, Chan LH, Zhang M, Arnal-Estape A, Zhao M, Balabaki A et al (2022) Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. *eLife* 11:e78163
- Cao B, Fang Z, Liao P, Zhou X, Xiong J, Zeng S, Lu H (2017) Cancer-mutated ribosome protein L22 (RPL22/eL22) suppresses cancer cell survival by blocking p53-MDM2 circuit. *Oncotarget* 8: 90651-90661
- Cao F, Townsend EC, Karatas H, Xu J, Li L, Lee S, Liu L, Chen Y, Ouillet P, Zhu J et al (2014) Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. *Mol Cell* 53: 247-261
- Cervia LD, Shibue T, Borah AA, Gaeta B, He L, Leung L, Li N, Moyer SM, Shim BH, Dumont N et al (2023) A Ubiquitination Cascade Regulating the Integrated Stress Response and Survival in Carcinomas. *Cancer Discovery* 13: 766-795
- Chacon Simon S, Wang F, Thomas LR, Phan J, Zhao B, Olejniczak ET, Macdonald JD, Shaw JG, Schlund C, Payne W et al (2020) Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. *J Med Chem* 63: 4315-4333
- Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, Rioux N, Munchhof MJ, Jin L, Jacques SL et al (2015) A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. *Nat Chem Biol* 11: 432-437
- Chang L, Xia J (2023) MicroRNA Regulatory Network Analysis Using miRNet 2.0. *Methods Mol Biol* 2594: 185-204

- Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, Mortimore M, O'Donnell ME, Pinder JL, Reaper PM et al (2011) Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. *J Med Chem* 54: 2320-2330
- Chen W, Chen X, Li D, Wang X, Long G, Jiang Z, You Q, Guo X (2021a) Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity. *Eur J Med Chem* 223: 113677
- Chen W, Chen X, Li D, Zhou J, Jiang Z, You Q, Guo X (2021b) Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia. *J Med Chem* 64:8221-8245
- Chen Y, Anastassiadis K, Kranz A, Stewart AF, Arndt K, Waskow C, Yokoyama A, Jones K, Neff T, Lee Y et al (2017) MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia. *Cancer Cell* 31: 755-770 e756
- Chen ZW, Liu B, Tang NW, Xu YH, Ye XY, Li ZM, Niu XM, Shen SP, Lu S, Xu L (2014) FBXL5-mediated degradation of single-stranded DNA-binding protein hSSB1 controls DNA damage response. *Nucleic Acids Res* 42: 11560-11569
- Choi M, Chang CY, Clough T, Broudy D, Killeen T, MacLean B, Vitek O (2014) MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. *Bioinformatics* 30: 2524-2526
- Costa-Mattioli M, Walter P (2020) The integrated stress response: From mechanism to disease. *Science* 368:eaat5314
- Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M (2014) Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol Cell Proteomics* 13: 2513-2526
- Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol* 26: 1367-1372
- Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M (2011) Andromeda: a peptide search engine integrated into the MaxQuant environment. *J Proteome Res* 10: 1794-1805
- Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y et al (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. *Cancer Cell* 20: 53-65
- Di Vona C, Bezdán D, Islam AB, Salichs E, Lopez-Bigas N, Ossowski S, de la Luna S (2015) Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA polymerase II CTD kinase. *Mol Cell* 57: 506-520
- Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29: 15-21
- Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R et al (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nature Biotechnology* 34: 184-191
- Drygin D, Lin A, Bliesath J, Ho CB, O'Brien SE, Proffitt C, Omori M, Haddach M, Schwaebe MK, Siddiqui-Jain A et al (2011) Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. *Cancer Res* 71: 1418-1430
- Eischer N, Arnold M, Mayer A (2023) Emerging roles of BET proteins in transcription and co-transcriptional RNA processing. *Wiley Interdiscip Rev RNA* 14: e1734
- El Hassouni B, Mantini G, Immordino B, Peters GJ, Giovannetti E (2019) CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage. *Molecules* 24:4445
- Fischer M (2017) Census and evaluation of p53 target genes. *Oncogene* 36: 3943-3956
- Florian AC, Woodley CM, Wang J, Grieb BC, Slota MJ, Guerrazzi K, Hsu CY, Matlock BK, Flaherty DK, Lorey SL et al (2022) Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells. *NAR Cancer* 4: zcac007
- Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, Marine JC (2006) Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. *Proc Natl Acad Sci U S A* 103: 3232-3237
- Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER, 3rd, Barretina J, Gelfand ET, Bielski CM, Li H et al (2019) Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature* 569: 503-508

- Gockler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, Becker W (2009) Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. *Febs J* 276: 6324-6337
- Goudarzi KM, Lindstrom MS (2016) Role of ribosomal protein mutations in tumor development (Review). *Int J Oncol* 48: 1313-1324
- Grebien F, Vedadi M, Getlik M, Giamb Bruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D et al (2015) Pharmacological targeting of the Wdr5-MLL interaction in C/EBPalpha N-terminal leukemia. *Nat Chem Biol* 11: 571-578
- Guarnaccia AD, Rose KL, Wang J, Zhao B, Popay TM, Wang CE, Guerrazzi K, Hill S, Woodley CM, Hansen TJ et al (2021) Impact of WIN site inhibitor on the WDR5 interactome. *Cell Reports* 34: 108636
- Guarnaccia AD, Tansey WP (2018) Moonlighting with WDR5: A Cellular Multitasker. *J Clin Med* 7:21
- Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T et al (2017) Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. *Nature Medicine* 23: 1046-1054
- Jayaraman S, Chittiboyina S, Bai Y, Abad PC, Vidi PA, Stauffacher CV, Lelievre SA (2017) The nuclear mitotic apparatus protein NuMA controls rDNA transcription and mediates the nucleolar stress response in a p53-independent manner. *Nucleic Acids Res* 45: 11725-11742
- Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, Sanjana NE, Zhang F (2017) Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. *Nat Protoc* 12: 828-863
- Jung JH, Bae S, Lee JY, Woo SR, Cha HJ, Yoon Y, Suh KS, Lee SJ, Park IC, Jin YW et al (2011) E3 ubiquitin ligase Hades negatively regulates the exonuclear function of p53. *Cell Death Differ* 18: 1865-1875
- Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA et al (2013) Mutational landscape and significance across 12 major cancer types. *Nature* 502: 333-339
- Karatas H, Li Y, Liu L, Ji J, Lee S, Chen Y, Yang J, Huang L, Bernard D, Xu J et al (2017) Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction. *J Med Chem* 60: 4818-4839
- Karatas H, Townsend EC, Cao F, Chen Y, Bernard D, Liu L, Lei M, Dou Y, Wang S (2013) High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. *J Am Chem Soc* 135: 669-682
- Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A (2021) Fast gene set enrichment analysis. *bioRxiv*: 060012
- Labun K, Montague TG, Krause M, Torres Cleuren YN, Tjeldnes H, Valen E (2019) CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. *Nucleic Acids Res* 47: W171-W174
- Laham AJ, Saber-Ayad M, El-Awady R (2021) DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis. *Cell Mol Life Sci* 78: 603-619
- Laham-Karam N, Pinto GP, Poso A, Kokkonen P (2020) Transcription and Translation Inhibitors in Cancer Treatment. *Front Chem* 8: 276
- Lai A, Kennedy BK, Barbie DA, Bertos NR, Yang XJ, Theberge MC, Tsai SC, Seto E, Zhang Y, Kuzmichev A et al (2001) RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest. *Mol Cell Biol* 21: 2918-2932
- Lan F, Bayliss PE, Rinn JL, Whetstone JR, Wang JK, Chen S, Iwase S, Alpatov R, Issaeva I, Canaani E et al (2007) A histone H3 lysine 27 demethylase regulates animal posterior development. *Nature* 449: 689-694
- Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. *Nat Methods* 9: 357-359
- Larionova TD, Bastola S, Aksinina TE, Anufrieva KS, Wang J, Shender VO, Andreev DE, Kovalenko TF, Arapidi GP, Shnaider PV et al (2022) Alternative RNA splicing modulates ribosomal composition and determines the spatial phenotype of glioblastoma cells. *Nat Cell Biol* 24: 1541-1557
- Lauria F, Tebaldi T, Bernabò P, Groen EJN, Gillingwater TH, Viero G (2018) riboWaltz: Optimization of ribosome P-site positioning in ribosome profiling data. *PLoS Comput Biol* 14: e1006169
- Lenard A, Xie HM, Pastuer T, Shank T, Libbrecht C, Kingsley M, Riedel SS, Yuan ZF, Zhu N, Neff T et al (2020) Epigenetic regulation of protein translation in KMT2A-rearranged AML. *Exp Hematol* 85: 57-69

- Li D, Yu X, Kottur J, Gong W, Zhang Z, Storey AJ, Tsai YH, Uryu H, Shen Y, Byrum SD et al (2022) Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. *Oncogene* 41: 3328-3340
- Li DD, Chen WL, Xu XL, Jiang F, Wang L, Xie YY, Zhang XJ, Guo XK, You QD, Sun HP (2016) Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. *Eur J Med Chem* 118: 1-8
- Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, Irizarry RA, Liu JS, Brown M, Liu XS (2014) MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. *Genome Biol* 15: 554
- Liao Y, Smyth GK, Shi W (2014) featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 30: 923-930
- Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P (2015) The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst* 1: 417-425
- Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP (2011) Molecular signatures database (MSigDB) 3.0. *Bioinformatics* 27: 1739-1740
- Litovchick L, Florens LA, Swanson SK, Washburn MP, DeCaprio JA (2011) DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. *Genes Dev* 25: 801-813
- Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15: 550
- Macdonald JD, Chacon Simon S, Han C, Wang F, Shaw JG, Howes JE, Sai J, Yuh JP, Camper D, Alicia BM et al (2019) Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5-MYC Protein-Protein Interaction. *J Med Chem* 62: 11232-11259
- Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. 2011 17: 3
- McDaniel KF, Wang L, Soltwedel T, Fidanze SD, Hasvold LA, Liu D, Mantei RA, Pratt JK, Sheppard GS, Bui MH et al (2017) Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor. *J Med Chem* 60: 8369-8384
- McGlincy NJ, Ingolia NT (2017) Transcriptome-wide measurement of translation by ribosome profiling. *Methods* 126: 112-129
- Muys BR, Anastasakis DG, Claypool D, Pongor L, Li XL, Grammatikakis I, Liu M, Wang X, Prasanth KV, Aladjem MI et al (2021) The p53-induced RNA-binding protein ZMAT3 is a splicing regulator that inhibits the splicing of oncogenic CD44 variants in colorectal carcinoma. *Genes Dev* 35: 102-116
- O'Leary MN, Schreiber KH, Zhang Y, Duc AC, Rao S, Hale JS, Academia EC, Shah SR, Morton JF, Holstein CA et al (2013) The ribosomal protein Rpl22 controls ribosome composition by directly repressing expression of its own paralog, Rpl22i1. *PLoS Genet* 9: e1003708
- Oh E, Mark KG, Mocciano A, Watson ER, Prabu JR, Cha DD, Kampmann M, Gamarra N, Zhou CY, Rape M (2020) Gene expression and cell identity controlled by anaphase-promoting complex. *Nature* 579: 136-140
- Peltonen K, Colis L, Liu H, Trivedi R, Moubarek MS, Moore HM, Bai B, Rudek MA, Bieberich CJ, Laiho M (2014) A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. *Cancer cell* 25: 77-90
- Pfister AS (2019) Emerging Role of the Nucleolar Stress Response in Autophagy. *Front Cell Neurosci* 13: 156
- Pfister AS, Keil M, Kuhl M (2015) The Wnt Target Protein Peter Pan Defines a Novel p53-independent Nucleolar Stress-Response Pathway. *J Biol Chem* 290: 10905-10918
- Philippe L, van den Elzen AMG, Watson MJ, Thoreen CC (2020) Global analysis of LARP1 translation targets reveals tunable and dynamic features of 5' TOP motifs. *Proc Natl Acad Sci U S A* 117: 5319-5328
- Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, Ahern J, Khot A, Hein N, George AJ et al (2016) Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. *Oncotarget* 7: 49800-49818
- Quinlan AR, Hall IM (2010) BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* 26: 841-842

- Radzisheuskaya A, Shliha PV, Grinev V, Lorenzini E, Kovalchuk S, Shlyueva D, Gorshkov V, Hendrickson RC, Jensen ON, Helin K (2019) PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia. *Nat Struct Mol Biol* 26: 999-1012
- Rallapalli R, Strachan G, Cho B, Mercer WE, Hall DJ (1999) A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. *J Biol Chem* 274: 8299-8308
- Raught B, Gingras AC, Sonenberg N (2001) The target of rapamycin (TOR) proteins. *Proc Natl Acad Sci U S A* 98: 7037-7044
- Ritz C, Baty F, Streibig JC, Gerhard D (2015) Dose-Response Analysis Using R. *PLoS One* 10: e0146021
- Sani E, Hannan KM, Xuan J, Yan S, Ahern JE, Trigoufas AS, Brajanovski N, Son J, Chan KT, Kondrashova O et al (2020) CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. *Nat Commun* 11: 2641
- Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide libraries for CRISPR screening. *Nat Methods* 11: 783-784
- Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrto CI, Barbacci EG et al (1995) Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. *J Med Chem* 38: 3806-3812
- Senisterra G, Wu H, Allali-Hassani A, Wasney GA, Barsyte-Lovejoy D, Dombrowski L, Dong A, Nguyen KT, Smil D, Bolshan Y et al (2013) Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. *The Biochemical Journal* 449: 151-159
- Shen S, Park JW, Lu ZX, Lin L, Henry MD, Wu YN, Zhou Q, Xing Y (2014) rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. *Proc Natl Acad Sci U S A* 111: E5593-5601
- Sherr CJ (2001) The INK4a/ARF network in tumour suppression. *Nat Rev Mol Cell Biol* 2: 731-737
- Shinsky SA, Monteith KE, Viggiano S, Cosgrove MS (2015) Biochemical reconstitution and phylogenetic comparison of human SET1 family core complexes involved in histone methylation. *J Biol Chem* 290: 6361-6375
- Shore D, Albert B (2022) Ribosome biogenesis and the cellular energy economy. *Curr Biol* 32: R611-R617
- Shorstova T, Foulkes WD, Witcher M (2021) Achieving clinical success with BET inhibitors as anti-cancer agents. *Br J Cancer* 124: 1478-1490
- Siladi AJ, Wang J, Florian AC, Thomas LR, Creighton JH, Matlock BK, Flaherty DK, Lorey SL, Howard GC, Fesik SW et al (2022) WIN site inhibition disrupts a subset of WDR5 function. *Sci Rep* 12: 1848
- Smith T, Heger A, Sudbery I (2017) UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. *Genome research* 27: 491-499
- Souers AJ, Levenson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ et al (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nature Medicine* 19: 202-208
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 102: 15545-15550
- Temaj G, Chichiarelli S, Eufemi M, Altieri F, Hadziselimovic R, Farooqi AA, Yaylim I, Saso L (2022) Ribosome-Directed Therapies in Cancer. *Biomedicines* 10
- Teuscher KB, Chowdhury S, Meyers KM, Tian J, Sai J, Van Meveren M, South TM, Sensintaffar JL, Rietz TA, Goswami S et al (2023) Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models. *Proc Natl Acad Sci U S A* 120: e2211297120
- Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, Zhang H, Liu Z, Ernst P, Koretzky GA et al (2010) MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. *Cancer Cell* 17: 148-159
- Thomas LR, Adams CM, Wang J, Weissmiller AM, Creighton J, Lorey SL, Liu Q, Fesik SW, Eischen CM, Tansey WP (2019) Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. *Proc Natl Acad Sci U S A* 116: 25260-25268

- Thomas LR, Wang Q, Grieb BC, Phan J, Foshage AM, Sun Q, Olejniczak ET, Clark T, Dey S, Lorey S et al (2015) Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. *Mol Cell* 58: 440-452
- Tian J, Teuscher KB, Aho ER, Alvarado JR, Mills JJ, Meyers KM, Gogliotti RD, Han C, Macdonald JD, Sai J et al (2020) Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. *J Med Chem* 63: 656-675
- Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, Gill S, Harrington WF, Pantel S, Krill-Burger JM et al (2017) Defining a Cancer Dependency Map. *Cell* 170: 564-576 e516
- UniProt Consortium (2021) UniProt: the universal protein knowledgebase in 2021. *Nucleic Acids Res* 49: D480-d489
- Wang F, Jeon KO, Salovich JM, Macdonald JD, Alvarado J, Gogliotti RD, Phan J, Olejniczak ET, Sun Q, Wang S et al (2018) Discovery of Potent 2-Aryl-6,7-Dihydro-5 H-Pyrrolo[1,2- a]imidazoles as WDR5 WIN-site Inhibitors Using Fragment-Based Methods and Structure-Based Design. *J Med Chem* 61: 5623-5642
- Wu Q, Medina SG, Kushawah G, DeVore ML, Castellano LA, Hand JM, Wright M, Bazzini AA (2019) Translation affects mRNA stability in a codon-dependent manner in human cells. *eLife* 8: e45396
- Xiao Z, Zou Q, Liu Y, Yang X (2016) Genome-wide assessment of differential translations with ribosome profiling data. *Nat Commun* 7: 11194
- Xu H, Di Antonio M, McKinney S, Mathew V, Ho B, O'Neil NJ, Santos ND, Silvester J, Wei V, Garcia J et al (2017) CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. *Nat Commun* 8: 14432
- Xuan J, Gitareja K, Brajanovski N, Sanij E (2021) Harnessing the Nucleolar DNA Damage Response in Cancer Therapy. *Genes (Basel)* 12: 1156
- Yadav B, Wennerberg K, Aittokallio T, Tang J (2015) Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. *Comput Struct Biotechnol J* 13: 504-513
- Yu X, Li D, Kottur J, Shen Y, Kim HS, Park KS, Tsai YH, Gong W, Wang J, Suzuki K et al (2021) A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. *Sci Transl Med* 13: eabj1578
- Zhao PY, Yao RQ, Zhang ZC, Zhu SY, Li YX, Ren C, Du XH, Yao YM (2022) Eukaryotic ribosome quality control system: a potential therapeutic target for human diseases. *Int J Biol Sci* 18: 2497-2514
- Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, Pessia A, Tang J (2022) SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets. *Genomics Proteomics Bioinformatics* 20:587-596
- Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, Barsyte-Lovejoy D, Al-awar R, Katona BW, Shilatifard A et al (2015) Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. *Nature* 525: 206-211
- Zona S, Bella L, Burton MJ, Nestal de Moraes G, Lam EW (2014) FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. *Biochim Biophys Acta* 1839: 1316-1322

Figure 1




Figure 1 – figure supplement 1




Figure 1—figure supplement 2




Figure 2




Figure 2—figure supplement 2




Figure 3








Figure 3—figure supplement 1

A



B







Figure 4





Figure 4—figure supplement 1



Figures





Figure 5—figure supplement 1

A



B





Figure 5—figure supplement 2

A



B




Figure 5 - figure supplement 3




Figure 6




Figure 6—figure supplement 1




Figure 6—figure supplement 2




Figure 6—figure supplement 3

